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SUMMARY 
Novel non-leaving groups were employed in this dissertation to synthesize 
platinum complexes which can assist in the understanding or improvement of 
anticancer action. Emphasis was placed on (NS)-chelate and (NN)-chelate 
platinum complexes. 
Bidentate (NS)-donor ligands were used as non-leaving ligands in the synthesis of 
platinum(II) complexes with iodo, chloro, bromo and oxalato groups as leaving 
groups. These complexes were synthesized and studied since many questions 
regarding the interaction of sulfur-donors and platinum still exist. These relate to 
thermodynamic and kinetic factors and their influence on anticancer action. In this 
dissertation the properties of novel platinum(II) complexes of a bidentate ligand 
having an aromatic nitrogen-donor atom in combination with a thioethereal sulfur 
atom capable of forming a five-membered ring with platinum(II) were studied. The 
general structure of the (NS)-ligands used was 2-((alkylthio)methyl)pyridine. Alkyl 
groups used were methyl, ethyl, propyl, benzyl and phenyl. 
Amine complexes of platinum have been studied extensively in the past. However, 
attention was given to novel aspects of substituted pyridine and imidazole ligands 
and their corresponding complexes. Amongst these are 2-(2-
methylaminoethyl)pyridine, 1-methyl-2-methylaminoethylimidazole and 1-methyl-2-
methylaminobenzylimidazole. The leaving groups included chloro, bromo and 
oxalato. 
Mononitroplatinum(IV) complexes were prepared using novel synthetic methods. 
Selected platinum(II) amine complexes were used as starting materials for this 
synthesis. Some of these compounds exhibit promising anticancer behaviour. 
(Trans-(R,R)-1,2-diaminocyclohexane)(oxalato)(mononitrochloro)platinum(IV) is a 
particularly good anticancer agent and has been patented internationally. 
All these complexes were characterized using mass spectrometry, 
chromatography, thermogravimetric analysis, kinetic aspects such as ligand 
exchange rates and finally their anticancer action against three different cancer 
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cell lines was evaluated via cytotoxicity assays. Some of the compounds exhibited 
particularly good anticancer potential. 
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CHAPTER 1:   
INTRODUCTION 
1 HISTORICAL BACKGROUND 
The biological activity of platinum compounds was first discovered by Rosenberg 
in 1965 during an experiment designed to examine the effects of electric fields on 
the growth of Escherichia coli bacteria.1 Rosenberg’s discovery that the 
platinum(II) complex cis-PtCl2(NH3)2 (commonly known as cisplatin) and the 
platinum(IV) complex cis-PtCl4(NH3)2 inhibit cell division sparked wide-spread 
interest in the development of platinum-based antitumour drugs. Cisplatin was first 
synthesized in 1844 in Turin by Michele Peyrone (hence it was originally known as 
Peyrone’s chloride), but it was only in 1965 that its antitumour activity was 
discovered. The first cancer patient received cisplatin treatment in 1971.2
H3
N Cl
H3N Cl
Pt
 The 
structure of cisplatin is shown in figure 1.1. 
 
Figure 1:1 Structure of cisplatin 
Cisplatin was subsequently used with great success in the treatment of ovarian 
and testicular cancer, as well as supplementing the treatment of various 
carcinomas including oropharyngeal, bronchogenic, cervical and bladder 
carcinomas.3 Presently, cisplatin remains one of only three universally applied 
platinum anticancer agents. The dose of cisplatin that can safely be administered 
is limited, however, by the severe toxic side effects of this compound, including 
nephrotoxicity, neurotoxicity and emetogenesis.4 Another disadvantage of cisplatin 
as anticancer agent is the fact that certain tumours have natural resistance to this 
compound, whilst others acquire cisplatin resistance following the initial treatment. 
This phenomenon is a result of a combination of factors, including reduced 
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platinum transport, increased cytoplasmic detoxification via an increase in 
glutathione and/or metallothionein concentrations, enhanced DNA repair, and 
increased cellular tolerance to Pt-DNA adducts.5 Thousands of direct cisplatin 
analogues have been synthesized.6
1.1 SOME PLATINUM COMPOUNDS COMMONLY APPLIED 
 Unfortunately, most of these were rejected 
during preclinical or early clinical trials.   
Despite the vast number of cisplatin analogues as well as numerous platinum 
compounds that are structurally dissimilar to cisplatin that have been developed, 
there are still only three platinum compounds that are universally accepted for the 
treatment of cancer patients. The first generation anticancer agent cisplatin and 
second generation cisplatin analogue cis-diammine(1,1-cyclobutanedicarboxylato) 
platinum(II) (commonly known as carboplatin) are universally approved to treat a 
variety of cancers, either as single agents or in combination with other drugs. 
Oxaliplatin, (trans-R,R-1,2-diaminocyclohexane)oxalatoplatinum(II)), has shown 
great potential for the treatment of colorectal cancer, such that this compound has 
also received universal acceptance as chemotherapeutic agent.7,8,9,10
2
 There are a 
number of platinum complexes that have been approved for anticancer treatment 
only in certain countries. Examples include nedaplatin [cis-diammine-glycolato-
O,O’-platinum(II)] and lobaplatin (1,2-diaminemethylcyclobutaneplatinum(II) 
lactate). In Japan, nedaplatin has been approved for the treatment of a variety of 
carcinomas, including those of the lungs, testes, head and neck, bladder, ovaries, 
oesophagus and cervix. Nedaplatin was found to be cross-resistant with cisplatin, 
however.  This drug displayed lower nephrotoxicty, but higher myelosuppression 
than cisplatin.11 Myelosuppression was, in fact, the dose-limiting factor. Lobaplatin 
(approved for anticancer treatment in China) was found to exhibit significant 
antitumour activity, even in cisplatin-resistant cell lines, i.e. this compound is non-
cross-resistant with cisplatin. Nephro- and neurotoxicities of lobaplatin are also 
much lower than those of cisplatin.12 The structures of some of the commonly 
applied platinum anticancer agents are shown in figure 1.2. 
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Figure 1:2 Structures of some widely used platinum anticancer compounds 
1.2 PROPERTIES OF PLATINUM(II) AND PLATINUM(IV) 
The principal oxidation states of platinum as well as palladium are II and IV. 
Platinum(II) and palladium(II) are d8 systems, with the majority of complexes 
formed exhibiting the square planar geometry. Ligand exchange rate (to be 
discussed in detail later in paragraph 1.5) is a very important factor in anticancer 
action. Ligand exchange rates of palladium(II) complexes are approximately 105 
times faster than those of platinum(II) complexes. This can mainly be related to 
the lesser nephelauxetic effect of the 4d transition metal as compared to the 5d. In 
the case of palladium(II), the pentacoordinated activated state is formed more 
readily than in the case of platinum(II). In the case of the latter, pentacoordinated 
complexes are almost unknown. This is the main reason why palladium(II) 
complexes are not as suitable for anticancer treatment as their platinum(II) 
analogues. In general, the ligand exchange rates of platinum(II) complexes are 
slow enough to allow for efficient anticancer action, mainly due to the increased 
nephelauxetic effect of the 5d transition metal. 
Platinum(II) has a high affinity for σ-donor π-acceptor ligands such as R3P, CN-, 
NO2-, alkenes, alkynes, etc., but a low affinity for σ-donor π-donor ligands such as 
fluoro and oxo ligands.13 The current universally accepted platinum anticancer 
agents are all in the more reactive platinum(II) oxidation state. These complexes 
tend to react with the proteins in the bloodstream. Platinum(IV) complexes, in 
contrast, are much less reactive since these have octahedral configurations and 
are 18 electron systems in which coordination expansion is energetically difficult.14
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1.3 MODE OF ACTION  
Cisplatin is a neutral, square planar coordination complex of platinum(II). In this 
complex, the platinum is coordinated to two chloro ligands and two ammonia 
groups, where the chloro ligands are in the cis-geometry. The ammonia groups 
are strongly coordinated to platinum(II) and are therefore known as the non-
leaving groups. The chloro ligands, in contrast, are easily substituted by 
nucleophiles and are referred to as the leaving groups. In aqueous solution, both 
chloro ligands slowly dissociate from the coordination sphere of platinum(II) and 
are replaced by water molecules, resulting in an equilibrium consisting of 
unhydrolyzed, partially hydrolyzed and fully hydrolyzed platinum species.15,16
19
 The 
equilibrium composition is determined by the concentration of chloride ions, and at 
high chloride concentrations unhydrolyzed cisplatin is the predominant species in 
solution.  After intravenous administration of this compound, cisplatin remains in 
the form of the neutral complex, since the relatively high chloride concentration 
(~100 mM) in the blood suppresses ionization of the chloro ligands. Cisplatin 
enters the cell by passive diffusion, as indicated by the fact that this process does 
not have a pH optimum, and is unaffected by the presence of structural 
analogues.17
 Pt(NH3)2Cl2    +    H2O                               Pt(NH3)2Cl(H2O)+    +    Cl-        Eq. 1.1 
The product of the hydration reaction is a cationic mono-aquated species that can 
react with nucleophilic sites on macromolecules. This species subsequently binds 
to an N7-atom of a guanine or adenine base in the DNA (see figure 1.3), displacing 
the water molecule in a comparatively fast reaction to form a monofunctional 
adduct. The second chloro ligand can also ionize and be replaced by a water 
molecule, and if there is another potentially reactive site nearby, the 
monofunctional adduct can react further to form intrastrand and interstrand 
cross-links.
 When cisplatin enters the cancer cell, where the chloride ion 
concentration is significantly lower (~4 mM), one of the chloro ligands ionizes. This 
reaction can be represented by the following equation: 
18  
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Figure 1:3 Structure of (a) guanine and (b) adenine 
 
 
Figure 1:4 Cisplatin adduct formation19
Platinum(II) complexes of trans geometry have been found to be less active in vivo 
and to possess significantly less cytotoxic activity than the cis isomers in vitro. 
These properties appear to be related to the weaker inhibition of DNA replication 
and transcription by transplatin than by cisplatin adducts, comparatively fast repair 
of transplatin adducts in contrast to those of cisplatin and the inability of transplatin 
to produce 1,2-intrastrand cross-links. It has been shown that 1,2-intrastrand 
cross-links are the most frequent adducts formed by cisplatin. Transplatin, in turn, 
induces monoadducts which may be repaired or undergo further rearrangements 
forming DNA–DNA cross-links as well as DNA–protein cross-links. Transplatin 
also forms significant amounts of interstrand cross-links between cytosine and 
guanine nucleobases of double-stranded DNA, but it was proven that formation of 
interstrand cross-links by this compound does not change the stability and 
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structure of DNA markedly.20
1.4 FACTORS INFLUENCING ANTICANCER ACTIVITY 
  
The major factors influencing anticancer activity are discussed in the following 
paragraphs. 
1.4.1 Kinetic behaviour 
The rate of ligand exchange has an important influence on the efficacy of an 
anticancer agent. Too rapid ligand exchange leads to detoxification before the cancer 
cells are reached, in conjunction with severe systemic toxicity. Too slow ligand 
exchange, in turn, leads to inefficient anticancer behaviour. Ligand exchange of 
square planar platinum(II) complexes generally occurs by an associative process 
(SN2 mechanism) involving a distorted pentacoordinated  intermediate. In the case of 
stereochemical crowding, however, ligand exchange normally occurs by a 
dissociative pathway. These mechanisms are illustrated in figure 1.5. 
 
Figure 1:5 The dissociative (SN1) and associative (SN2) paths21 
An important factor to take into consideration when studying the kinetic behaviour 
of complexes is the so-called “trans effect”. This phenomenon refers to the 
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capability of a coordinated ligand to labilize a ligand situated trans to it in a square 
planar platinum(II) complex. The normal order of trans directing capability is as 
follows:  CN- ~ CO ~ olefins > thioethers ~ H+ ~ arsines ~ phosphines > SC(NH2)2 
~ CH3 > C6H5- ~ NO2- ~ I- ~ SCN- > Br- ~ Cl- > amines ~ NH3 ~ OH- ~ H2O. This 
sequence clearly illustrates that sulfur-donor ligands behave very different to the 
bulk of the ligands found in the human body (chloro, amine and aquo ligands).  
It is also obvious that sulfur donors will play a dominant role in the case of “soft” 
heavy metals introduced into body fluid. Sulfur donors like glutathione, methionine 
(see structures shown in figure 1.6), etc., are in fact used to demetallate mercury, 
lead, and other heavy metals from the human body.21
HO N
H
H
N
OH
OO O
O
SH
NH2
Glutathione
 It has also been observed 
that cisplatin is removed via urine with the Pt(II) bonded to sulfur atoms. It is 
therefore essential to have an understanding of all the aspects of ligand exchange. 
(a)     (b) 
H S
H2N
OH
O
Methionine  
Figure 1:6 Structure of (a) glutathione and (b) methionine 
The trans directing sequence shown above was mainly based on the kinetics of 
reaction of square planar platinum(II) complexes of pyridine.21 There are, however, 
a number of other factors which result in exceptions to the general rule. These 
include the following: 
(i) Nature of co-ligands 
The nature of co-ligands can greatly influence the behaviour of a coordinated 
ligand in platinum(II) and platinum(IV) complexes. This is exemplified by the 
observation that the trans effect of sulfur-donor ligands is lower than expected in 
the presence of co-ligands with highly electronegative donor atoms such as 
nitrogen or oxygen. Such properties are referred to as biphilic. 
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(ii) Steric hindrance 
In sterically hindered systems, size and shape of the nucleophile becomes more 
important than the “normal order” of nucleophilicity. This may lead to reversals in 
nucleophilicity. It should also be noted that the position of the steric effect plays a 
significant role, e.g. a 2-methyl substituted pyridine cis to the leaving group has a 
much bigger effect than when trans to the leaving group.21, 22
(iii) Bond lengths and force constants 
 
Factors such as bond lengths, force constants and stretching frequencies can be 
important. The bond length of a Pt-Cl bond, for example, is determined by the 
electronegativity of the donor atom trans to it. This is clearly illustrated by the bond 
length of the Pt-Cl bond trans to NH3 (2.21 Å) as compared to the longer Pt-Cl 
bond length (2.37 Å) trans to a P(CH3)3 group. This will have a notable influence 
on the lability of the leaving group. 
(iv) Effect of the cis ligand 
When adjacent ligands have weak trans effects, such as in Pt(NH3)2Cl2, the cis 
effect dominates greatly. In this case, Cl->NH3 is “normal” but in reality the chloro 
ligand ionizes more readily than the ammine group. 
(v) The chelate effect 
The chelate effect of ligands such as oxalate provides enhanced stability which 
slows down the rate of ligand exchange. 
1.4.2 Stereochemical factors 
Stereochemical crowding has a significant impact on the behaviour of anticancer 
agents. Three major interrelated effects of stereochemical crowding are mentioned 
here. 
(i) Stereochemical crowding leads to a decrease in ligand exchange rate. In 
addition, it limits detoxification of anticancer agents by providing a barrier 
for donation of the large sulfur atoms present in biological compounds such 
9 
as glutathione. 
(ii) It also plays a role in the level of replicative bypass of platinum-DNA 
adducts and in the repair mechanism. 
(iii) It causes significant hydrophobicity which facilitates passive diffusion 
through cell walls, thereby assisting cell uptake of the agents.23
1.4.3 S-N interactions 
 
Sulfur-donor ligands have great trans labilizing potential in square planar 
platinum(II) complexes due to their high nucleophilicity. It is also important to note 
that platinum(II) has a high affinity for these ligands, which leads to the formation 
of complexes that are thermodynamically very stable. There are two 
distinguishable types of sulfur-donor ligands. The first type consists of σ-donor 
π-acceptor ligands such as thioethers and sulfoxides. The second type consists of 
σ-donor π-donor ligands such as thiols and compounds like thiourea. The latter 
group forms more thermodynamically stable complexes with platinum(II) than the 
former. Therefore, thiols bond irreversibly with platinum(II), whereas thioethers can 
be replaced by aromatic nitrogens such as the N7-atom of guanine.24
 
 Previous 
ligand exchange studies have shown that the order of replacement is 
thiols (glutathione) > guanine N7 > thioether (methionine) > adenine N7. This 
sequence can be understood by considering space-filling models as well as 
charge distribution values of the ligands. The space-filling models and charge 
distribution values of guanine and adenine are shown in figure 1.7 and figure 1.8, 
respectively. 
Figure 1:7 Space-filling and charge distribution models for guanine. 
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Figure 1:8 Space-filling and charge distribution models for adenine. 
A comparison of the N7-atoms of guanine and adenine reveals the following: 
(i) The N7-atom of guanine is less stereochemically crowded than that of 
adenine. 
(ii) The negative charges on the two atoms adjacent to the N7-atoms are 
higher in the case of guanine as compared to adenine, resulting in a greater 
potential of induction by the platinum(II) 
(iii) At pH~7, the N7-atom of adenine will be protonated to a greater extent than 
that of guanine due to the greater σ basicity of the former. Consequently, 
the N7-atom of guanine will be more available for coordination to 
platinum(II). 
(iv) The stronger hydrogen-bonding capability of guanine also plays a role in 
the stability of its platinum-DNA adduct.25,26
The difference between the two types of sulfur atoms is just as significant. The 
thiol S can very readily be deprotonated by the “soft” 5d transition-metal 
(platinum), so that the neutral ligand becomes a monoanionic one with all the 
covalent capability available to satisfy the nephelauxetic character of platinum(II). 
In contrast, the thioethers are neutral sulfur-donor ligands.  
Space-filling models of typical biothio-compounds were constructed to aid in the 
development of methods that can be used to limit the effect of sulfur donation. 
Figure 1.9 shows the space-filling and charge-distribution models of cysteine, a 
typical example of a sulfur-containing molecule present in biological systems. 
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Figure 1:9 Space-filling and charge distribution models of cysteine.   
It is clear that the sulfur atom is much larger than an aromatic nitrogen donor 
atom. Ligand exchange of platinum(II) complexes occurs via a distorted 
pentacoordinated∗ intermediate, therefore stereochemical crowding of the 
platinum(II) square planar complex will have bigger negative effects on the ligand 
exchange of the bulky sulfur atom than on that of the smaller nitrogen atom. 
Deactivation by sulfur-containing biomolecules such as glutathione is recognized 
as one of the most important mechanisms of platinum drug resistance. Sterically 
hindered platinum complexes are of great interest as potential anticancer drugs.27
1.4.4 Biocompatibility 
 
It has also been observed that chelated nitrogen donors increase thermodynamic 
stability, which provides a bigger barrier towards replacement by thioether sulfur 
atoms.  
Solubility of a platinum complex within the bloodstream enhances the 
biocompatibility of such a compound. Another important requirement for 
biocompatibility is the ability of the compound to easily pass through the cell 
membrane to reach its target, i.e. cellular DNA. Practically any molecule will 
diffuse across the lipid bilayer of the plasma membrane down its concentration 
gradient, but the rate of diffusion will differ according to the size and 
hydrophobicity of the molecule. It can be assumed that cisplatin and analogous 
                                            
∗ Either trigonal bipyramidal or square pyramidal 
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compounds will cross the membrane by means of passive diffusion since they are 
small and uncharged. Multinuclear platinum compounds which are positively 
charged, however, are also able to reach the cellular DNA, therefore it is likely that 
there are a number of different mechanisms involved in the transport of platinum 
across membranes.  
(i) Solubility 
Cisplatin is administered intravenously due to the limitations imposed by the 
relatively low solubility of cisplatin in aqueous solution. The aqueous solubility can 
be enhanced by replacing the unidentate chloro ligands of cisplatin with 
carboxylates, oxalate, glycolate or malonate or even by introducing polar groups 
as part of the non-leaving moiety. A number of compounds have been synthesized 
using this premise, including carboplatin and oxaliplatin.  
(ii) Membrane Transport 
Approximately half of the initial drug uptake rate is due to passive diffusion while 
the other half occurs by facilitated diffusion through a gated channel. Increasing 
the hydrophobicity of anticancer agents can enhance membrane transport, since 
the interior of the cell membrane consists of hydrophobic hydrocarbon tails. An 
example of such a compound is JM216 [bis(acetato)ammine-
dichloro(cyclohexylamine)platinum(IV)], which was found to enter the cell 
predominantly through passive diffusion due to its increased lipophilicity.4,28 
Platinum(IV) complexes of this type have been studied extensively and include 
compounds such as JM221 [ammine(cyclohexylamine)dibutyratodichloro-
platinum(IV)] and C5-OHP-C1. 29
Another advantage of increased hydrophobicity is that it enhances the mechanism 
by which 1,2-intrastrand cross-links create a hydrophobic notch at the damage 
 
Resistance due to decreased platinum accumulation can thus be avoided by 
increasing the lipophilicity of anticancer agents, since the more lipophilic 
compounds will enter the cell more easily. Carboxylate, carbonate and carbamate 
ligands are ideally suited for use in such complexes, since they contain both polar 
and lipophilic moieties.  
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site. This reduces nucleotide excision repair by shielding the damage site from 
damage-recognition proteins and consequently improves anticancer activity. 
Previous studies have shown that there is a direct correlation between 
hydrophobicity and antitumour activity. In one such experiment, three platinum 
analogues with increased hydrophobic nature were synthesized. Anticancer 
screening of these three platinum compounds indicated that the most hydrophobic 
molecule (methylpyridineplatinum) was the most cytotoxic, followed by the second 
most hydrophobic (methylpyrazineplatinum), while pyridineplatinum showed the 
weakest cytotoxic activity. 30,31
(iii) Biologically Active Carrier Groups 
 
An effective solution to the problems associated with the lack of tumour selectivity 
and severe adverse reactions associated with cisplatin and its analogues lie in 
delivering the drug to the tumour cells using advanced drug delivery systems. This 
can be done by attaching any one of a variety of different carrier molecules to the 
normal chloride binding areas, leading to a greater specificity of the tumour cells 
for these compounds. Platinum complexes can, for example, be attached to 
doxorubicin, an anthracycline antibiotic which intercalates DNA and is commonly 
used in the treatment of various types of cancer. Platinum has also been attached 
to oestrogen analogues that bind to selective oestrogen receptors in the cytoplasm 
which ultimately facilitates transport across the cell membrane. Specific tissues 
can be targeted by attaching the appropriate moieties to platinum complexes.  
DNA intercalators have also been attached to platinum complexes with the 
expectation that such compounds would localize in the vicinity of the DNA. Such 
complexes with anilinoacridine and acridinecarboxamide have been shown to 
exhibit improved anticancer activity as compared to the original platinum complex, 
but not relative to the carrier ligands.32, 33
1.4.5 Mode of bonding to DNA 
 
Bonding of the platinum(II) centre of cisplatin analogues to the N7-atom of guanine 
in preference to that of adenine has already been discussed in paragraph 1.5.3. 
Another important aspect related to bonding of anticancer agents to DNA is the 
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formation of monofunctional versus bifunctional intrastrand adducts. 
Thermodynamic stability plays a crucial role in the stabilization of Pt-DNA adducts. 
It has been noted that 1,2-intrastrand adducts involving two neighbouring guanine 
nucleobases or a guanine and neighbouring adenine are the major forms of DNA 
adducts.34
19
 Studies done in vitro demonstrate that DNA treated with cisplatin 
contains approximately 65% 1,2-d(GpG), 25% 1,2-d(ApG), and 5–10% 1,3-d(Gp-
NpG) intrastrand cross-links, and a small percentage of interstrand cross-links and 
monofunctional adducts.  Evidence strongly favours intrastrand adducts as the 
lesions largely responsible for cytotoxic action.35 A distortion of the DNA base-
pairs at the platination site alters alignment of the DNA in the binding site of DNA 
polymerase, slowing down replication. Monofunctional binding is much less 
effective with regard to cytotoxicity.  
Interstrand cross-links have proven to be particularly effective at thwarting excision 
repair. It should also be noted that DNA repair is severely impaired by the 
formation of interstrand adducts (i.e. involving both strands of DNA) since the 
repair enzymes cannot use the information in the complimentary strand as a 
template for re-synthesis. This accounts for the success of di- and trinuclear 
platinum compounds as antitumour compounds.36
1.5 RECENT ADVANCES IN PLATINUM ANTICANCER RESEARCH 
  
One of the focal points of continued research in the field of platinum chemotherapy 
is combating the high systemic toxicity of traditional platinum anticancer agents by 
designing drug delivery systems capable of delivering these compounds 
selectively to the tumour cells. An interesting example of this strategy is the 
encapsulation of cisplatin and carboplatin in the hollow protein cage of the iron 
storage protein ferritin, which can be internalized by some tumour tissues.37  
Another effective method for delivering drugs to specific target sites involves the 
use of polymeric micelles as drug carriers. Figure 1.10 shows the typical structure 
of a polymeric micelle. 
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Figure 1:10 Polymeric micelles can be used as intelligent nano-carriers for drug 
delivery38
Specific drug delivery to cancer cells require the following processes to occur: 
prolonged drug circulation, extravasation and local retention in tumour tissues. The 
size and surface properties of the drug carrier will influence all of these processes.
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Platinum(IV) anticancer drugs can also be used to overcome some of the 
problems associated with cisplatin and its analogues.39 The great kinetic inertness 
of Pt(IV) complexes as compared to their Pt(II) analogues stabilizes these 
compounds, while the two extra ligands on the octahedral metal centre allow for 
modification of pharmacokinetic parameters. Intracellular reduction of platinum(IV) 
to platinum(II) is usually required for activation and subsequent cytotoxicity. 
Platinum(IV) compounds in effect provide better ways of delivering the active 
platinum(II) anticancer agents to the tumour cells. 
Another recent experiment relying on the photochemical activation of platinum(IV) 
drugs, rather than spontaneous intracellular reduction, to release active antitumour 
agents has also been reported.40,41
1.6 FOCUS OF THIS DISSERTATION 
  
The complexities of sulfur-donor interaction were mentioned earlier in this chapter. 
Although some progress was made in understanding the action of these ligands, a 
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number of uncertainties still exist.42, 43, 44
Diamine complexes of platinum(II) were also studied, bearing in mind the new 
advances in this particular field. This was done in order to study the influence of 
stereochemistry of the non-leaving group. The results of this investigation are 
discussed in chapter 5. Another promising aspect of diamine complexes, namely 
those of their mononitrohaloplatinum(IV) analogues, became of great interest after 
the discovery of cis-diamminetrichloromononitroplatinum(IV) (CPA-7). A series of 
novel species of this type has been synthesized and characterised. In this study, 
the novel aspect is that oxalatoplatinum(II) species were used as precursors for 
the oxidation to platinum(IV). This was done to avoid the formation of numerous 
secondary products as found in previous studies on mainly platinum(II)chloro 
species.
  In this dissertation, therefore, the properties 
of a novel type of sulfur-donor ligand, namely one in which a thioethereal sulfur is 
combined with an aromatic nitrogen in a chelate ligand, was synthesized and 
complexed to platinum(II). A detailed motivation for this study is given in each of 
chapters 3 and 4. The results of this work are also described in the latter chapters.  
45
Chapter 2 will focus on the experimental procedures and analytical techniques 
followed. 
 The results of these proved to be major improvements over previous 
studies and will be discussed in chapter 6. Some further motivation for this work 
will also be found in chapter 6. 
The work was performed emphasizing the development of improved synthetic 
methods, and characterization of the complexes was achieved by mass spectral, 
other spectral, thermogravimetric and in one instance X-ray structural analysis. 
Final analyses included ligand exchange rates and efficiency in anticancer action 
tested on three different cancer cell lines. 
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CHAPTER 2:   
EXPERIMENTAL PROCEDURES 
2       INTRODUCTION 
This chapter describes the synthesis and characterization of the ligands as well as 
synthesis and some general characterization of the platinum and palladium 
coordination complexes discussed in the subsequent chapters. Detailed synthetic 
methodology will be provided to enable reproducibility of these procedures. The 
instrumentation employed in the analysis of the ligands and complexes will be 
described here, including some of the analytical procedures performed at other 
centres where appropriate facilities were not available in this department. 
2.1 ANALYSIS TECHNIQUES 
2.1.1 Elemental analysis 
Microanalysis for C, H, N, and S was performed at the University of Cape Town. 
The samples were analysed by a Thermo Flash 1112 Elemental Analyzer. 
2.1.2 Infrared spectroscopy 
Infrared spectra were recorded using an Excalibur HE FTS3100 infrared 
spectrophotometer in the range of 3800-200 cm-1 using the single beam mode.  
Solid samples were compressed with dry potassium bromide into discs and 
scanned with nitrogen gas as reference. Liquid samples were spread as a thin film 
between two sodium chloride plates and scanned using the empty plates as 
reference. 
2.1.3 Thermal gravimetric analysis 
TGA was performed on a TGA 2050 Thermogravimetric Analyzer using TA 
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instrument-Advantage software for Thermal Analysis.  The data obtained was 
analysed on TA Universal Analysis 2000.  The sample was heated between room 
temperature and 400°C ramping the temperature at 5°C/min.  
2.1.4 NMR Spectrometry 
The 300.13 MHz 1H-NMR spectra were recorded on a Bruker 300 MHz 
spectrometer using SiMe4 as the internal standard. The samples were prepared 
using deuterated chloroform (CDCl3) as solvent. 
2.1.5 Inductively-coupled plasma emission mass spectroscopy 
The platinum and palladium concentrations of the samples prepared for the 
solubility studies were analysed using a Perkin Elmer SCIEX Elan-6100 ICP-MS 
Spectrometer. The ICP settings used are given below in Table 2.1. 
Table 2:1 General ICP settings used 
 
 
 
 
 
 
The standards were prepared in an aqueous medium containing 0.1 M HCl in the 
range of 5-1000 µg/l.  Samples for analysis were diluted appropriately and 
prepared in a 0.1 M HCl matrix. 
2.1.6 Electrospray Ionization Mass Spectrometry (ESI-MS) 
Measurements were carried out on an LCQ Deca instrument (Finnigan, San 
 SETTING 
RF Power 1.4 kW 
Coolant gas 15 L/min 
Nebulizer gas flow 0.7 L/min 
Dwell time per AMU 50 ms 
Sweeps/reading 10 
Readings/replicate 2 
Replicate 10 
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Jose,CA, USA) in either positive or negative ionisation mode. For infusion studies 
the samples, in appropriate solvent, were directly infused at a flow rate of 10 
μl/min using a 500 μl Unimetrics HPLC syringe and the instrument’s own syringe 
pump. A 50% MeCN/10 mM ammonium formate/0.06% formic acid solution was 
used as sheath liquid at a flow rate of 150 μl/min. The tip of the fused silica 
capillary (i.d. 100 μm, o.d. 190 μm) was positioned 0.5 to 1.0 mm inside the tip of 
the stainless steel sprayer capillary allowing direct contact with the analysis 
solution. The electrospray atmospheric pressure ionization probe was maintained 
in position 2. The parameters of the instrument were tuned using an infusion 
solution of Pt(dach)Cl2 in MeCN (10 μM at 10 μl/min). 
Positive ion mode instrument settings 
The instrument parameters were tuned using the ammonium adduct [M+NH4]+ with 
the following values: nitrogen sheath gas flow rate 80 arbitrary units, nitrogen 
auxiliary gas flow rate 20 arbitrary units, sprayer voltage 3.5 kV, capillary voltage 
46.0 V, tube lens offset 55.0 V, multipole 1 offset -5.75 V, lens voltage -28.0 V, 
multipole 2 offset -10.00 V, multipole RF amplitude (V p-p) 400 V, entrance lens - 
62.0 V and 100 ms maximum injection time using automatic gain control. 
Negative ion mode instrument settings 
The parameters of the instrument were tuned using the formate adduct 
[M+HCOO]- to the following values: nitrogen sheath gas flow rate 80 arbitrary 
units, nitrogen auxiliary gas flow rate 20 arbitrary units, sprayer voltage 5.0 kV, 
capillary voltage -12.0 V, tube lens offset 5.0 V, multipole 1 offset 5.25 V, lens 
voltage 46.0 V, multipole 2 offset 10.00 V, multipole RF amplitude (V p-p) 400 V, 
entrance lens 38.0 V and 100 ms maximum injection time using automatic gain 
control. 
2.1.7 MSn experiments 
Fragmentation studies were carried out using an isolation width of at least 5 Da 
i.e. the ion isolation window was adjusted to allow passage of all major isotopes in 
the platinum isotope profile with a 2.5 mass unit margin on the high (198Pt) and 
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low (194Pt) end of the target. Activation amplitude and activation time were 
adjusted individually for each fragmentation within the ranges 5 - 50% for 
activation amplitude and 40 - 100ms for activation time, always resulting in 
maximum abundance of the fragment ion examined. The transfer capillary 
temperature was kept constant at 200ºC, being the lowest temperature to provide 
sufficient desolvation. Spectra were obtained after averaging the acquired spectra. 
More spectra were required for averaging when low concentrations or dirty 
samples were analysed. 
2.1.8 HPLC-UV 
LC separations were performed on a Waters HPLC system consisting of a WISP 
717 autosampler, 600E quaternary gradient pump and 484 variable wavelength 
UV-Vis detector.  
2.1.9 Column separations 
Two different kinds of HPLC separation columns were used during this study. The 
specifications are as follows: 
Table 2:2  Specifications of HPLC columns 
Supplier Phase  Dimensions 
YMC Hydrosphere C18 120 Å 5 μm  250 x 4.6 mm 
Phenomenex Curosil PFP 5 μm 250 x 4.6 mm 
2.1.10 FAB Mass spectrometry 
FAB mass spectra were obtained from the University of Potchefstroom.  The 
spectra were recorded on a VG70-70E mass spectrometer using a VG2035 data 
system.  All samples were analysed under positive-ion operating conditions.  An 
Ion Tech saddle-field using xenon as bombardment gas (8 kV, 1 mA) was 
employed to record the spectra.  The mass spectrometer was operated at 6 kV 
and the magnetic analyser was scanned at 5 s per decade between 500-100 Da. 
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The matrix used was glycerol or 3-nitrobenzylalcohol. 
2.1.11 Solubility Studies 
The solubilities of the complexes were measured by suspending the compound in 
a solvent mixture (2 ml) containing 10 % calf serum and 90 % RPMI 1640 and 
stirring at 25°C for 1 hour after which the mixture was centrifuged for 5 minutes at 
5000 rpm's.  The supernatant liquor was diluted so that the palladium/platinum 
concentrations were suitable for ICP-MS analysis.  In most cases a 5000 times 
dilution was sufficient for palladium complexes whereas a 1000 or 2000 times 
dilution proved ideal in the case of the platinum complexes. 
2.1.12 Crystallographic Analysis 
A full X-ray structure determination was performed on (Trans-(R,R)-1,2-
diaminocyclohexane)(oxalato)(mononitrochloro)platinum(IV) (Mar4.1.4).  The 
diffraction data was collected at the University of the Witwatersrand using a 
Bruker SMART 1K CCD area detector diffractometer with graphite monochromated 
MoKα radiation (50 kV, 30 mA).  The collection method involved ω-scans of width 
0.3°.  Data reduction was carried out using SAINT+ 46 and absorption corrections 
were made using the program SADABS.47 
The WinGX 1.64.02 48 suite of programs was used to solve the crystal structures 
using either direct methods or the Pattersen approach. Refinement was done 
using SHELXS-97. 49 Non-hydrogen atoms were first refined isotropically followed 
by anisotropic refinement by full matrix least-squares calculations based on F2. 
Hydrogen atoms were positioned geometrically and allowed to ride on their 
respective parent atoms with one exception. Torsional angles and least squares 
planes of selected atoms were calculated using PARST.50  Diagrams were 
generated using ORTEP. 51  
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2.1.13 Cytotoxicity Evaluation 
All the complexes prepared in this dissertation were tested for anticancer action 
according to known literature methods by the Biochemistry department of the 
Nelson Mandela Metropolitan University under the supervision of Dr. M. van de 
Venter.  The compounds were tested on colon (HT29), breast (MCF7) and 
cervical cancer (HeLa) cell lines. A summary of the general method is given 
below.   
Cytotoxicity was determined by a modified MTT assay (Sigma).  Cells in 
exponential growth were trypsinized, counted using a haemocytometer and diluted 
to a density of 30 000 cells per mL.  200µL aliquots of cell suspensions were 
added to each well of a 96-well microtiter plate and incubated for 24 hours.  The 
novel platinum-containing compounds were screened for cytotoxicity using 10 and 
100µM concentrations.  Cisplatin (10 and 100µM concentrations) served as 
reference.  The spent medium was removed from the 96-well plate and aliquots 
(200µL) of the treatments added to the wells in quadruplicate.  The plate was 
incubated in a 37°C-5% CO2 humidified incubator for 48 hours.  A 5mg/mL stock 
solution of MTT was prepared in PBSA and used to prepare a 1mg/mL solution of 
MTT in growth medium, which was applied to wells in 200µL aliquots.  The plate 
was incubated for 3 hours before the MTT was removed and replaced by 200µL of 
DMSO to dissolve MTT formazan.  The plates were agitated on a shaker for 5 
minutes, before the absorbance was read at 540nm on a multi-well scanning 
spectrophotometer.  The values obtained were used to determine the percentage 
inhibition of cell growth that these drugs cause. 
2.2 SYNTHESIS OF STARTING MATERIALS 
2.2.1 K2PtCl6 
Pure platinum metal (99.99 %) (30 g, 154 mmol) was dissolved in a mixture of 300 
mL aqua regia and 50 mL distilled water at an elevated temperature. The solution 
was concentrated to a paste by heating. The paste was subsequently dissolved in 
150 mL concentrated HCl and again boiled down to a paste. The paste was once 
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again dissolved in concentrated HCl (200 mL) and concentrated down to a 
minimal volume, after which 25 mL of concentrated HCl was added to it and the 
solution diluted to 250 mL in a volumetric flask.   
Chemically pure potassium chloride (KCl, 51 g, 684 mmol) was dissolved in 350 
mL of distilled water and added dropwise to the abovementioned platinum solution 
while stirring. An equal volume (600 mL) of absolute ethanol was added and the 
mixture was allowed to stand at 2ºC for 2 hours, after which the yellow K2PtCl6 
was filtered and washed twice with 40 mL portions of 50 % ethanol, once with 25 
mL of 99 % ethanol, and three times with 30 mL aliquots of diethyl ether. The 
product was subsequently dried in the oven at 50ºC. 
Yield:    98.5 % 
2.2.2 K2PtCl4 
K2PtCl6 (30g, 61.7mmol) was suspended in 300 mL distilled water and heated for 
10-15 minutes using a water bath at 80-90°C.  A saturated aqueous solution of 
sulfur dioxide (SO2) was added in 10 mL portions over 5 minute intervals.  The 
time intervals were gradually lengthened as the reduction neared completion.  
Addition of SO2 was stopped when a very red solution without any traces of yellow 
was formed.  The solution was concentrated and allowed to cool, after which it 
was placed in the fridge for 2 hours to promote complete crystallization.  The 
resultant red crystalline K2PtCl4 was filtered, washed three times with 10 mL 
acetone portions and allowed to air dry in the oven overnight at 40°C.     
Yield: 97% 
2.2.3 K2Pt(oxalate)2·2H2O 
K2PtCl4 (2.08g, 5.0mmol) and 16 equivalents of K2(C2O4)·H2O (14.72g, 79.9mmol) 
were dissolved in 30mL distilled water at 90°C and stirred for 1 hour whilst 
maintaining the temperature at 90°C, after which the reaction mixture was allowed 
to cool for 2 hours at 5°C.  The resultant K2Pt(oxalate)2.2H2O precipitate was 
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filtered and washed 5 times with 15 mL distilled water, once with 10 mL acetone 
and allowed to air dry at 50°C in an oven.   
Yield: 95%. 
2.2.4 (Trans-R,R-1,2-diaminocyclohexane)oxalatoplatinum(II) (Oxaliplatin) 
2.2.4.1 Preparation of Pt(dach)Cl2 
85 g diaminocyclohexane (0.744 mol) were dissolved in approximately 350 ml 
water and added in portions to a solution of K2PtCl4, prepared by dissolving 309 g 
(0.744 mol) in 6.2 L water, over a period of 30 minutes. The mixture was stirred at 
30 °C for 18-24 h, or until the supernatant liquor was visibly decolourized (pale 
yellow). The solid yellow Pt(dach)Cl2 was collected by suction filtration, washed 
with water, ethanol and ether, in that order, and dried at 50 °C overnight.  
Yield: 90% 
2.2.4.2 Preparation of Tetrabutylammonium Oxalate solution 
212 g oxalic acid (1.68 mol) was dissolved in 2.2 L (~3.3 mol) of a 40 % 
tetrabutylammonium hydroxide solution and stirred at room temperature for 1 h in 
a sealed vessel, out of direct light. No additional water was added. The pH was 
measured and adjusted to 7 with the residual tetrabutylammonium hydroxide 
solution and / or small measured masses of oxalic acid. 
2.2.4.3 Preparation of Oxaliplatin 
The tetrabutylammonium oxalate solution, prepared as described above, was 
added to 256 g Pt(dach)Cl2, followed by 28 L isoamyl alcohol. The mixture was 
stirred in a closed vessel and thermostatically maintained at an internal 
temperature of 83-86 °C for 12 h. Temperature control is important as the reaction 
does not proceed well at temperatures below 80 °C. During this time, the 
Pt(dach)Cl2 gradually disappeared and was replaced by white oxaliplatin which 
precipitated out of the reaction solution. The appearance of oxaliplatin usually 
became evident after 4-5 h. The reaction mixture was cooled to 4 °C, the 
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precipitated oxaliplatin collected by suction filtration and washed with several small 
volumes of dry acetone (to remove residual solvent). The product may have a 
slight yellow tinge due to contamination with unreacted Pt(dach)Cl2. 
Yield: 75-83%  
2.2.4.4 Purification 
The oxaliplatin was purified by recrystallization from purified water at 70-75 °C. As 
a rule, to ensure a sufficiently concentrated solution, 50-60 mL water was used per 
gram of crude material. Typically the water was preheated to the desired 
temperature (preheating would reduce the volume of dissolved oxygen) and the 
crude oxaliplatin added. Stirring at the elevated temperature was continued until 
90-95% of the material dissolved, where after the solution was filtered rapidly via 
suction to remove the undissolved solids. The liquor was flushed with nitrogen and 
cooled to 4 °C for 15-20 h in a sealed vessel during which time crystallization 
commenced. The crystals were collected by suction filtration, washed with minimal 
volumes of dry acetone and dried at 50 °C. 
Yield: 50%  
Further crops were collected by reducing the volume of mother liquor under 
vacuum at 70 °C. These crops were often slightly yellow due to the coprecipitation 
of Pt(dach)Cl2. The latter was conveniently removed by washing with very small 
quantities of dmf until the yellow colouration was visibly reduced. As oxaliplatin is 
also soluble in dmf, this procedure was carried out rapidly. Thereafter, the 
oxaliplatin was washed with dry acetone, to remove the dmf, and dried. 
2.2.5 cis-Diammineoxalatoplatinum(II) (Cisox) 
Cisox was prepared by two different methods, namely by the silver method, and 
by direct ligand exchange in a mixed solvent system. 
2.2.5.1 The Silver Method 
(i) Synthesis of Pt(NH3)2I2 
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3.063 g (7.4 mmol) K2PtCl4 was dissolved in 30 mL distilled water. 6 Equivalents 
(7.797 g, 47 mmol) of potassium iodide were dissolved in 10 mL distilled water 
and added to the above solution, after which the mixture was stirred at room 
temperature for 25 minutes. 1.875 mL of concentrated NH3 was added to the 
reaction mixture and the resulting suspension was stirred overnight at room 
temperature in order to facilitate complete precipitation of Pt(NH3)2I2 (Cisiodide). 
The product was subsequently filtered, washed with distilled water, ethanol and 
diethyl ether, and dried in an oven at 50ºC.  Yield of cisiodide: 81 % 
(ii) Silver Reaction 
2.824 g (5.8 mmol) cisiodide was suspended in 30 mL distilled water. 1.892 g 
(11.1 mmol; 1.9 equivalents) of silver nitrate was dissolved in 3 mL water and  
added to the suspension.  The reaction mixture was stirred overnight at room 
temperature in the dark, centrifuged and filtered. 1.077 g (5.8 mmol; 1 equivalent) 
of potassium oxalate monohydrate was dissolved in 2 mL distilled water and 
added to the filtrate, after which the resulting suspension was stirred overnight at 
room temperature to facilitate complete precipitation of the product (Cisox). The 
white precipitate was filtered, washed with acetone and dried in an oven at 50ºC. 
Yield of cisox: 67 %. 
2.2.5.2 Direct Ligand Exchange 
1.05 g of oxalic acid was dissolved in 11.2 mL 40 % tetrabutylammonium 
hydroxide solution, after which the pH of this solution was adjusted to 7. This 
solution was stirred vigorously with 1.000 g (3.3 mmol) of cis-
Diamminedichloroplatinum(II) (cisplatin) and 140 mL of isoamyl alcohol at 75ºC for 
10 hours. In this mixture the ratio of cisplatin:oxalate was 1:2.5, the ratio of 
alcohol:water was 95:5 and the amount of cisplatin in the reaction mixture 6.7 g/L. 
During this time, a white precipitate of cis-diammineoxalatoplatinum(II) formed. 
After reaction, the white solids were recovered by filtration at a crude yield of 96 
%. Purification was effected by recrystallization from water at 75ºC to furnish 0.5 g 
of pure cis-diammineoxalatoplatinum(II). Yield of cisox: 47 %. 
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2.3 SYNTHESIS OF (NS)-DONOR LIGANDS 
2.3.1 2-((Methylthio)methyl)pyridine (mtmpy) 
8.202 g (50 mmol) 2-picolylchloride hydrochloride was dissolved in 50 ml ethanol. 
This solution was added dropwise to a solution of 22.756 mL (75 mmol) of a 21 % 
aqueous sodium thiomethoxide solution in 100 mL of a 5 % ethanolic NaOH 
solution. The resultant suspension was stirred overnight at room temperature, 
after which the solid sodium chloride was filtered off and 150 mL of a 0.2 M 
sodium carbonate solution was added to the filtrate. The mixture was extracted ten 
times with 50 mL chloroform portions. The chloroform portions were combined, 
washed four times with 50 mL aliquots of water, dried with anhydrous sodium 
sulfate and the excess chloroform evaporated under vacuum. The remaining oil 
was distilled under high vacuum to yield 2-methylthiomethylpyridine. 
Properties:  
The colourless liquid boiled between 65-70°C at 10 mTorr. 
Yield:  64% 
Analysis:  
Infrared Data (liquid film)  
ν(C=N) 1590, ν(C=C) 1474, ν(CH2-S) def 1435, ν(CH2-S) wag 1242 cm-1   
NMR data 
1H δ (300 MHz, CDCl3):  2.11 (3H, s, S-CH3), 3.83 (2H, s, CH2-S-CH3), 7.18-8.64 
(4H, m, Ar-H)  
2.3.2 2-((Ethylthio)methyl)pyridine (etmpy) 
The synthesis of etmpy employed an analogous method to that used in the case of 
mtmpy, except that ethanethiol was reacted with 2-picolylchloride hydrochloride in 
this case. 
Properties:  
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The light yellow liquid boiled between 72-74°C at 3 mTorr.  
Yield:  70% 
Analysis:  
Infrared Data (liquid film) 
ν(C=N) 1593, ν(C=C) 1473, ν(CH2-S) def 1435, ν(CH2-S) wag 1269 cm-1   
NMR Data  
1H δ (300 MHz, CDCl3):  1.15 (3H, t, CH2-CH3), 2.42 (2H, m, S-CH2-CH3), 3.85 
(2H, s, C-CH2-S), 7.13-8.44 (4H, m, Ar-H) 
2.3.3 2-((Propylthio)methyl)pyridine (prtmpy) 
The synthesis of prtmpy employed an analogous method to that used in the case 
of mtmpy, except that propanethiol was reacted with 2-picolylchloride 
hydrochloride in this case. 
Properties:  
The light yellow liquid boiled between 75-80°C at ±1 mTorr.  
Yield:  60% 
Analysis:  
Infrared Data (liquid film) 
ν(C=N) 1593, ν(C=C) 1470, ν(CH2-S) def 1435, ν(CH2-S) wag 1242 cm-1 
NMR Data  
1H δ (300 MHz, CDCl3):  0.96 (3H, t, CH2CH2-CH3), 1.65 (2H, m, CH2-CH2-CH3), 
2.37 (2H, t, CH2-CH2CH3), 3.75 (2H, s, C-CH2-S), 7.12-8.51 (4H, m, Ar-H) 
2.3.4 2-((Phenylthio)methyl)pyridine (phtmpy) 
The synthesis of phtmpy employed an analogous method to that used in the case 
of mtmpy, except that thiophenol was reacted with 2-picolylchloride hydrochloride 
in this case. 
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Properties:  
The clear yellow liquid boiled between 108-111°C at 13 mTorr. 
Analysis:  
Infrared Data (liquid film) 
ν(C=N) 1590, ν(C=C) 1473, ν(CH2-S) def 1436, ν(CH2-S) wag 1240 cm-1 
NMR Data  
1H δ (300 MHz, CDCl3):  4.36 (2H, s, S-CH2), 7.02-7.18 (5 benzene Ar-H),   7.22-
8.61 (4 pyridine Ar-H) 
2.3.5 2-((Benzylthio)methyl)pyridine (bzltmpy) 
The synthesis of bzltmpy employed an analogous method to that used in the case 
of mtmpy, except that benzyl mercaptan was reacted with 2-picolylchloride 
hydrochloride in this case. 
Properties:  
The clear yellow liquid boiled between 118-121°C at 9 mTorr. 
Analysis:  
Infrared Data (liquid film)  
ν(C=N) 1591, ν(C=C) 1473, ν(CH2-S) def 1435, ν(CH2-S) wag 1242 cm-1 
NMR Data  
1H δ (300 MHz, CDCl3):   3.67 (2H, s, S-CH2-phenyl), 3.98 (2H, s, S-CH2-pyridine), 
7.10-7.16 (5H, m, benzene Ar-H), 7.22-7.28 (2H, t, pyr-H), 7.72 (1H, t, pyr-H), 8.65 
(1H, t, pyr-H) 
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2.4 SYNTHESIS OF (NN)-DONOR LIGANDS 
2.4.1 1-Methyl-2-(methylaminoethyl)imidazole (mmaei) 
Step 1: 
A solution of 1-methylimidazole (46.8 g, 0.57 mol) dissolved in 675 mL of 40 % 
formaldehyde was refluxed for 3 days.  Sodium hydroxide (60 g, 1.5 mol) and 
2 liters of water were subsequently added and the volume reduced to 
approximately 500 mL where after the product was extracted 10 times with 
100 mL portions of chloroform.  The chloroform portions were combined, dried 
with anhydrous sodium sulfate and the solvent removed by distillation under 
vacuum.  A yellow oil of 1-methyl-2-hydroxymethylimidazole was obtained (Yield = 
62 %).   
Step 2: 
1-methyl-2-hydroxymethylimidazole (39.5 g, 0.35 mol) dissolved in 250 mL pre-
dried chloroform was added dropwise to thionyl chloride (154 mL, 2.12 mol) 
dissolved in 150 mL pre-dried chloroform while stirring the reaction solution in an 
ice-bath.  The solution was subsequently refluxed for 3½ hours after which the 
solvent and excess thionyl chloride was removed by distillation.  The solid 
obtained was triturated with a 1:1 mixture of diethylether:propan-2-ol.  The white 
precipitate of 1-methyl-2-chloromethylimidazole⋅HCl was filtered and rinsed twice 
with diethylether (Yield 87-89%).   
Step 3: 
1-Methyl-2-chloromethylimidazole (10.09 g, 0.06 mol) was dissolved in 200 mL 
toluene.  Solid sodium carbonate (12.27 g, 0.116 mol) and 70 % aqueous 
ethylamine solution (29.37 g, 0.456 mol) were added.  The mixture was refluxed 
for 24 hours and the resultant precipitate removed by filtration.  The solvent was 
removed by distillation and the remaining liquid distilled under vacuum. 
31 
Properties:  
The pale yellow liquid boiled between 78-80°C at 5 mTorr.  
Yield: 41 % 
Analysis:  
Infrared Data (liquid film)  
νmax(liquid film):  1670 (C=N), 1503 (C=C), 1458 (C=N-C=C ring vib), 1094(C-N-C 
asym str)cm-1 
NMR Data  
1H δ (300 MHz, CDCl3): 1.05 (3H, m, -NH-CH2-CH3), 1.99 (1H, s, -NH-CH2-CH3), 
2.61 (2H, m, -NH-CH2-CH3), 3.68 (3H, s, -N-CH3), 3.83 (2H, d, -NH-CH2-
Imidazole) and 6.76 (2H, m, -CH=CH-) 
2.4.2 1-Methyl-2-(methylaminobenzyl)imidazole (mmabi) 
The synthesis of mmabi employed an analogous method to that used in the case 
of mmaei, except that benzylamine was reacted with 1-methyl-2-chloromethyl 
imidazole in this case. 
Properties:  
The clear yellow viscous liquid boiled between 112-114°C at 8 mTorr.  
Yield: 59 % 
Analysis:  
Infrared data  
νmax(liquid film):  1674 (C=N), 1501 (C=C), 1456 (C=N-C=C ring vib.), 1105 (C-N-
C asym str.)cm-1 
NMR data  
1H δ (300 MHz, CDCl3):  2.49 (2H, t, NH-CH2), 3.48 (3H, s, CH3-N), 3.67 (2H, s, 
CH2-NH), 6.63 and 6.75 (2H, 2×s, Imidazole Ar-H), 7.48-7.92 (5H, m, Benzyl Ar-H) 
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2.5 SYNTHESIS OF PALLADIUM(II) COMPLEXES WITH NEUTRAL 
BIDENTATE (NS)-DONOR LIGANDS 
The preparations consisted of additions of solutions of the appropriate ligands to 
solutions of the appropriate metal salts. 
2.5.1 Chloro complexes 
A sample of K2PdCl4 (0.5 g, 1.5 mmol) was dissolved in 15 mL distilled water.  To 
this solution, 1.05 molar equivalent of the relevant ligand (1.6 mmol) dissolved in 2 
mL acetone was added dropwise.  The solution was stirred overnight at room 
temperature after which the resultant precipitate was filtered, washed once with 
3 mL distilled water and once with 3 mL acetone. The product was subsequently 
dried in an oven at 50°C. 
Properties 
Table 2:3  Colour and yields of the (NS)-chloro complexes of palladium(II) 
Complex Code Yield (%) Colour 
PdCl2(mtmpy) Mar7d.2 73 Dark yellow 
PdCl2(etmpy) Mar5d.2 74 Yellow 
PdCl2(prtmpy) Mar13d.2 78 Yellow 
PdCl2(phtmpy) Mar14d.2 86 Orange 
PdCl2(bzltmpy) Mar16d.2 93 Yellow 
Table 2:4  C, H, N, S elemental analysis of the (NS)-chloro complexes of palladium(II)  
Complex %C  %H  %N  %S  
 Exp. Calc. Exp. Calc. Exp. Calc. Exp. Calc. 
PdCl2(mtmpy) 26.7 26.6 2.9 2.9 4.7 4.4 10.3 10.1 
PdCl2(etmpy) 29.2 29.1 3.3 3.4 3.9 4.2 9.5 9.7 
PdCl2(ptmpy) 31.5 31.4 3.8 3.8 3.8 4.1 9.4 9.3 
PdCl2(phtmpy) 38.2 38.1 2.7 2.9 3.4 3.7 8.6 8.5 
PdCl2(bztmpy) 39.5 39.8 3.1 3.3 3.2 3.6 7.9 8.2 
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2.6 SYNTHESIS OF PLATINUM(II) COMPLEXES WITH NEUTRAL 
BIDENTATE (NS)-DONOR LIGANDS 
2.6.1 Chloro complexes 
Direct Method (Method I) 
K2PtCl4 (0.540 g, 2.0 mmol) was dissolved in 15 mL distilled water to which 1.05 
molar equivalent of the relevant ligand (1.6 mmol) dissolved in 2ml acetone was 
added dropwise.  The solution was stirred overnight at room temperature after 
which the resultant precipitate was filtered, washed with 3 mL cold distilled water 
and afterwards with 3 mL acetone. The product was then allowed to air dry in an 
oven at 50°C. 
Properties 
Table 2:5 Colour and yields of the (NS)-chloro complexes of platinum(II) prepared via 
the direct method  
Complex Code Yield (%) Colour 
PtCl2(mtmpy) Mar7.2 85 Pink 
PtCl2(etmpy) Mar5.2 84 Pink 
PtCl2(prtmpy) Mar13.2 90 Pink 
PtCl2(phtmpy) Mar14.2 59 Light pink 
PtCl2(bzltmpy) Mar16.2 83 Peach 
Table 2:6 Solubility data of the (NS)-chloro complexes of platinum(II) prepared via 
direct method  
Compound Code Solubility (g/l) Solubility (mM) 
Pt(mtmpy)Cl2 Mar7.2 0.229 0.565 
Pt(etmpy)Cl2 Mar5.2 0.553 1.319 
Pt(prtmpy)Cl2 Mar13.2 0.287 0.662 
Pt(phtmpy)Cl2 Mar14.2 0.376 0.805 
Pt(bzltmpy)Cl2 Mar16.2 0.270 0.561 
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Table 2:7 C, H, N, S elemental analysis of the (NS)-chloro complexes of platinum(II) 
prepared via the direct method 
Complex 
%C %H %N %S 
Exp. Calc. Exp. Calc. Exp. Calc. Exp. Calc. 
PtCl2(mtmpy) 20.8 20.8 2.2 2.2 2.9 3.5 8.1 7.9 
PtCl2(etmpy) 23.0 22.9 2.7 2.6 2.7 3.3 7.7 7.7 
PtCl2(prtmpy) 25.1 25.0 3.0 3.0 2.5 3.2 7.4 7.4 
PtCl2(phtmpy) 31.1 30.8 2.4 2.4 2.4 3.0 6.8 6.9 
PtCl2(bzltmpy) 32.7 32.4 2.8 2.7 2.2 2.9 7.2 6.7 
Silver Method (Method II) 
K2PtCl4(0.825 g, 1.99 mmol) was dissolved in 20 mL distilled water at room 
temperature to which were added dropwise while stirring 10 molar equivalents of 
potassium iodide(3.3g, 19.89 mmol) dissolved in 5 mL distilled water.  The mixture 
was allowed to stir for 20 minutes at room temperature after which 1.1 molar 
equivalent of the relevant ligand dissolved in 2 mL acetone was added dropwise 
while stirring to the platinum(II) solution. An extra 20 mL of acetone was added 
simultaneously with the addition of the ligand.  The reaction mixture was allowed 
to stir overnight at room temperature after which the precipitate was filtered and 
oven dried at 50°C.  The precipitate which formed was Pt(NS)I2. Some detail of 
the iodoplatinum(II) complexes synthesized according to the silver method are 
given in Table 2.8 
Table 2:8   Colour and yields of the (NS)-iodo complexes of platinum(II) 
Complex Code Yield (%) Colour 
PtI2(mtmpy) Mar7.5 95 Yellow 
PtI2(etmpy) Mar5.5 97 Dark Yellow 
PtI2(prtmpy) Mar13.5 90 Brown 
PtI2(phtmpy) Mar14.5 91 Brown 
PtI2(bzltmpy) Mar16.5 90 Orange 
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Table 2:9 Selected infrared data of the (NS)-iodo complexes of platinum(II)  
Compound C=N str (cm-1) 
C=C ring 
vib (cm-1) 
C=N-C=C 
ring vib 
(cm-1) 
CH2-S def 
(cm-1) 
CH2-S wag 
(cm-1) 
Pt–N 
(cm-1) 
Pt(mtmpy)I2 1608 1477 1444 1392 1265 473 
Pt(etmpy) I2 1607 1480 1443 1396 1269 480 
Pt(prtmpy) I2 1608 1482 1444 1399 1269 473 
Pt(phtmpy) I2 1609 1470 1444 1387 1268 484 
Pt(bzltmpy) I2 1617 1473 1457 1394 1271 476 
Table 2:10 C, H, N, S elemental analysis of the (NS)-iodo complexes of platinum(II) 
Complex 
%C %H %N %S 
Exp. Calc. Exp. Calc. Exp. Calc. Exp. Calc. 
PtI2(mtmpy) 14.8 14.3 1.7 1.5 2.5 2.4 5.5 5.5 
PtI2(etmpy) 16.5 16.0 2.0 1.8 2.0 2.3 5.5 5.3 
PtI2(prtmpy) 17.8 17.5 2.2 2.1 1.9 2.3 5.1 5.2 
PtI2(phtmpy) 22.6 22.2 1.7 1.7 2.0 2.2 5.2 4.9 
PtI2(bzltmpy) 24.5 23.5 2.2 2.0 1.6 2.1 5.5 4.8 
The Pt(NS)I2 which was synthesized in the above reaction was suspended in 1.95 
molar equivalents of silver nitrate dissolved in 8 mL distilled water and 2 mL acetone.  
The suspension was stirred overnight in the dark at room temperature.  The silver 
iodide and unreacted Pt(NS)I2 was removed by centrifugation.  10 Molar equivalents 
of LiCl was dissolved in a small amount of distilled water and added dropwise to the 
Pt(NS)(H2O)22+ solution causing the precipitation of Pt(NS)Cl2.  The reaction mixture 
was allowed to stir overnight at room temperature after which the precipitate was 
filtered, washed with a small portion of distilled water and oven dried at 50°C. 
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Table 2:11  Colour and yields of the (NS)-chloro complexes of platinum(II) prepared via 
silver method  
Complex Code Yield (%) Colour 
PtCl2(mtmpy) Mar7.2 22 Yellow 
PtCl2(etmpy) Mar5.2 60 Pale yellow 
PtCl2(prtmpy) Mar13.2 33 Pale yellow 
PtCl2(phtmpy) Mar14.2 55 Yellow 
PtCl2(bzltmpy) Mar16.2 72 Yellow 
Table 2:12 Solubility data of the (NS)-chloro complexes of platinum(II) prepared via 
silver method  
Compound Code Solubility (g/l) Solubility (mM) 
Pt(mtmpy)Cl2 Mar7.2 1.425 3.517 
Pt(etmpy)Cl2 Mar5.2 1.439 3.432 
Pt(ptmpy)Cl2 Mar13.2 1.207 2.786 
Pt(phtmpy)Cl2 Mar14.2 0.436 0.933 
Pt(bztmpy)Cl2 Mar16.2 0.391 0.812 
Table 2:13 Selected infrared data of the (NS)-chloro complexes of platinum(II) prepared via 
silver method  
Compound C=N str (cm-1) 
C=C 
ring vib 
(cm-1) 
C=N-C=C 
ring vib 
(cm-1)  
CH2-S 
def 
(cm-1) 
CH2-S 
wag 
(cm-1) 
Pt–N 
(cm-1) 
Pt–Cl 
(cm-1) 
Pt(mtmpy)Cl2 1612 1475 1448 1398 1273 473 338 
Pt(etmpy)Cl2 1611 1477 1441 1401 1262 477 333 
Pt(prtmpy)Cl2 1610 1473 1449 1400 1242 477 336 
Pt(phtmpy)Cl2 1610 1477 1440 1397 1274 485 337 
Pt(bzltmpy)Cl2 1608 1473 1450 1400 1245 480 328 
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Table 2:14 C, H, N, S elemental analysis of the (NS)-chloro complexes of platinum(II) 
prepared via the silver method 
Complex 
%C %H %N %S 
Exp. Calc. Exp. Calc. Exp. Calc. Exp. Calc. 
PtCl2(mtmpy) 20.6 20.8 2.2 2.2 3.4 3.5 8.1 7.9 
PtCl2(etmpy) 23.0 22.9 2.7 2.6 3.1 3.3 7.7 7.7 
PtCl2(prtmpy) 24.9 25.0 3.1 3.0 2.9 3.2 7.4 7.3 
PtCl2(phtmpy) 29.9 30.8 2.3 2.4 2.7 3.0 6.8 6.9 
PtCl2(bzltmpy) 32.5 32.4 2.7 2.7 2.7 2.9 7.0 6.7 
2.6.2 Bromo complexes 
The bromo complexes were synthesized from the appropriate iodo analogues by 
the silver method as described for the synthesis of chloro complexes. In this case, 
however, 10 molar equivalents of KBr were added to the Pt(NS)(H2O)22+ solution 
instead of 10 equivalents of LiCl. 
Table 2:15 Colour and yields of the (NS)-bromo complexes of platinum(II) prepared via 
the silver method  
Complex Code Yield (%) Colour 
PtBr2(mtmpy) Mar7.3 46 Yellow 
PtBr2(etmpy) Mar5.3 51 Yellow 
PtBr2(prtmpy) Mar13.3 34 Yellow 
PtBr2(phtmpy) Mar14.3 50 Yellow 
PtBr2(bzltmpy) Mar16.3 57 Yellow 
Table 2:16 Solubility data of the (NS)-bromo complexes of platinum(II) prepared via the 
silver method  
Compound Code Solubility (g/l) Solubility (M) 
Pt(mtmpy)Br2 Mar7.3 0.955 1.933 
Pt(etmpy)Br2 Mar5.3 1.003 1.974 
Pt(prtmpy)Br2 Mar13.3 0.652 1.249 
Pt(phtmpy)Br2 Mar14.3 0.631 1.135 
Pt(bzltmpy)Br2 Mar16.3 0.914 1.603 
38 
Table 2:17 Selected infrared data of the (NS)-bromo complexes of platinum(II) prepared 
via the silver method  
Compound C=N str (cm-1) 
C=C 
ring vib 
(cm-1) 
C=N-C=C 
ring vib 
(cm-1)  
CH2-S 
def 
(cm-1) 
CH2-S 
wag 
(cm-1) 
Pt–N 
(cm-1) 
Pt–Cl 
(cm-1) 
Pt(mtmpy)Br2 1610 1480 1447 1397 1272 473 354 
Pt(etmpy)Br2 1610 1475 1441 1400 1273 479 397 
Pt(prtmpy)Br2 1610 1472 1448 1403 1243 477 416 
Pt(phtmpy)Br2 1608 1474 1441 1387 1270 486 413 
Pt(bzltmpy)Br2 1608 1471 1433 1396 1267 478 397 
Table 2:18: C, H, N, S elemental analysis of the (NS)-bromo complexes of platinum(II) 
prepared via the silver method 
Complex 
%C %H %N %S 
Exp. Calc. Exp. Calc. Exp. Calc. Exp. Calc. 
PtBr2(mtmpy) 17.1 17.0 1.8 1.8 2.6 2.8 6.8 6.5 
PtBr2(etmpy) 19.2 18.9 2.2 2.2 2.3 2.8 5.9 6.3 
PtBr2(ptmpy) 20.9 20.7 2.7 2.5 2.4 2.7 6.1 6.1 
PtBr2(phtmpy) 26.1 25.9 2.0 2.0 2.4 2.5 6.0 5.8 
PtBr2(bztmpy) 27.3 27.4 2.4 2.3 2.2 2.5 5.8 5.6 
2.6.3 Oxalato complexes 
The oxalato complexes were synthesized from the appropriate iodo analogues by 
the silver method as described for the synthesis of chloro complexes. In this case, 
however, 1.1 molar equivalents of K2C2O4•2H2O were added to the Pt(NS)(H2O)22+ 
solution instead of 10 equivalents of LiCl. 
Table 2:19 Colour and yields of the (NS)-oxalato complexes of platinum(II) prepared via 
silver method  
Complex Code Yield (%) Colour 
Pt(C2O4)(mtmpy) Mar7.1 56 Grey 
Pt(C2O4)(etmpy) Mar5.1 51 White 
Pt(C2O4)(prtmpy) Mar13.1 14 Pale yellow 
Pt(C2O4)(phtmpy) Mar14.1 33 Pale yellow 
Pt(C2O4)(bzltmpy) Mar16.1 52 White 
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Table 2:20 Solubility data of the (NS)-oxalato complexes of platinum(II) prepared via the 
silver method  
Compound Code Solubility (g/l) Solubility (mM) 
Pt(mtmpy)Ox Mar7.1 0.960 2.273 
Pt(etmpy)Ox Mar5.1 1.705 3.908 
Pt(prtmpy)Ox Mar13.1 1.260 2.798 
Pt(phtmpy)Ox Mar14.1 1.900 3.923 
Pt(bzltmpy)Ox Mar16.1 1.422 2.853 
Table 2:21 Selected infrared data of the (NS)-oxalato complexes of platinum(II) prepared 
via the silver method  
Compound C=N str (cm-1) 
C=C 
ring vib 
(cm-1) 
C=N-C=C 
ring vib 
(cm-1)  
CH2-S 
def 
(cm-1) 
CH2-S 
wag 
(cm-1) 
Pt–N 
(cm-1) 
Pt–Cl 
(cm-1) 
Pt(mtmpy)Br2 1610 1480 1447 1397 1272 473 354 
Pt(etmpy)Br2 1610 1475 1441 1400 1273 479 397 
Pt(prtmpy)Br2 1610 1472 1448 1403 1243 477 416 
Pt(phtmpy)Br2 1608 1474 1441 1387 1270 486 413 
Pt(bzltmpy)Br2 1608 1471 1433 1396 1267 478 397 
Table 2:22 C, H, N, S elemental analysis of the (NS)-oxalato complexes of platinum(II) 
prepared via the silver method 
Complex 
%C %H %N %S 
Exp. Calc. Exp. Calc. Exp. Calc. Exp. Calc. 
Pt(mtmpy)Ox 25.4 25.6 2.2 2.2 3.6 3.3 7.8 7.6 
Pt(etmpy)Ox 26.9 27.5 2.8 2.5 3.2 3.2 6.9 7.4 
Pt(prtmpy)Ox 29.0 29.3 2.7 2.9 3.2 3.1 6.9 7.1 
Pt(phtmpy)Ox 34.3 34.7 2.5 2.3 2.7 2.9 6.7 6.6 
Pt(bzltmpy)Ox 35.9 36.2 2.6 2.6 2.7 2.8 6.6 6.4 
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2.7 SYNTHESIS OF PLATINUM(II) COMPLEXES WITH NEUTRAL 
BIDENTATE (NN)-DONOR LIGANDS 
2.7.1 Chloro complexes 
Silver Method 
K2PtCl4(0.923 g, 2.22 mmol) was dissolved in 20 ml distilled water at room 
temperature to which were added dropwise while stirring 10 molar equivalents of 
potassium iodide(3.7g, 22.2 mmol) dissolved in 5 ml distilled water.  The mixture 
was allowed to stir for 20 minutes at room temperature after which 1.05 molar 
equivalent of the relevant ligand dissolved in 2 ml acetone was added dropwise 
while stirring to the platinum(II) solution. An extra 20 ml of acetone were added 
simultaneously with the addition of the ligand.  The reaction mixture was allowed 
to stir overnight at room temperature after which the precipitate was filtered, 
washed with water and oven dried at 50°C.  The precipitate which formed was 
Pt(NN)I2. Some detail of the iodoplatinum(II) complexes synthesized according to 
the silver method are given in Table 2.23. 
Table 2:23 Colour and yields of the (NN)-iodo complexes of platinum(II) 
Complex Code Yield (%) Colour 
PtI2(2-picolylamine) Mar9.5 96 Dark yellow 
PtI2(mmaei) Mar1.5 81 Dark Yellow 
PtI2(mmabi) Mar6.5 90 Brown 
PtI2(maep) Mar8.5 93 Brown 
 Table 2:24 Selected infrared data of the (NN)-iodo complexes of platinum(II)  
Compound C=N str (cm-1) 
C=C ring vib 
(cm-1) 
C=N-C=C ring 
vib (cm-1) 
C-N-C asym str 
(cm-1) 
 PtI2(2-picolylamine) 1614 1559 1487 1111 
PtI2(mmaei) 1636 1517 1457 1086 
PtI2(mmabi) 1637 1515 1455 1086 
PtI2(maep) 1609 1566(s) 1481.0(m) 1088 
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Table 2:25 C, H, N  elemental analysis of the (NN)-iodo complexes of platinum(II)  
Complex 
%C %H %N 
Exp. Calc. Exp. Calc. Exp. Calc. 
PtI2(2-picolylamine) 13.1 13.0 1.9 1.3 4.7 5.0 
PtI2(mmaei) 14.7 14.3 2.8 2.2 7.3 7.2 
PtI2(mmabi) 23.1 22.2 2.8 2.2 6.5 6.5 
PtI2(maep) 16.7 16.4 2.5 2.1 4.6 4.8 
The Pt(NN)I2 which was synthesized in the above reaction was suspended in 1.95 
molar equivalents of silver nitrate dissolved in 8 ml distilled water and 2 ml acetone.  
The suspension was stirred overnight in the dark at room temperature.  The silver 
iodide and unreacted Pt(NS)I2 was removed by centrifugation.  10 Molar equivalents 
of LiCl were dissolved in a small amount of distilled water and added dropwise to the 
Pt(NN)(H2O)22+ solution causing the precipitation of Pt(NN)Cl2.  The reaction mixture 
was allowed to stir overnight at room temperature after which the precipitate was 
filtered, washed once with a small portion of distilled water and oven dried at 50°C. 
Table 2:26  Colour and yields of the (NN)-chloro complexes of platinum(II) prepared via 
silver method  
Complex Code Yield (%) Colour 
PtCl2(2-picolylamine) Mar9.2 66 Yellow 
PtCl2(mmaei) Mar1.2 72 Pale yellow 
PtCl2(mmabi) Mar6.2 76 Yellow 
PtCl2(maep) Mar8.2 67 Pale yellow 
Table 2:27 Solubility data of the (NN)-chloro complexes of platinum(II) prepared via 
silver method  
Compound Code Solubility (g/l) Solubility (mM) 
Pt(2-picolylamine)Cl2 Mar9.2 0.132 0.354 
Pt(mmaei)Cl2 Mar1.2 0.431 1.064 
Pt(mmabi)Cl2 Mar6.2 0.241 0.517 
Pt(maep)Cl2 Mar8.2 0.170 0.423 
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Table 2:28 Selected infrared data of the (NN)-chloro complexes of platinum(II) prepared 
via the silver method  
Compound C=N str (cm-1) C=C ring vib (cm-1) 
C=N-C=C ring 
vib (cm-1) 
C-N-C asym str 
(cm-1) 
PtCl2(2-picolylamine) 1617 1559 1491 1117 
PtCl2(mmaei) 1641 1518 1468 1090 
PtCl2(mmabi) 1636 1520 1456 1088 
PtCl2(maep) 1616 1558 1485 1094 
Table 2:29 C, H, N  elemental analysis of the (NN)-chloro complexes of platinum(II) 
prepared via the silver method 
Complex 
%C %H %N 
Exp. Calc. Exp. Calc. Exp. Calc. 
PtCl2(2-picolylamine) 19.2 19.3 2.3 1.9 7.1 7.5 
PtCl2(mmaei) 20.9 20.8 3.3 3.2 10.1 10.4 
PtCl2(mmabi) 30.2 30.9 3.4 3.0 8.7 9.0 
PtCl2(maep) 23.8 23.9 3.1 3.0 6.6 7.0 
2.7.2 Bromo complexes 
The bromo complexes were synthesized from the appropriate iodo analogues by 
the silver method as described for the synthesis of chloro complexes. In this case, 
however, 10 molar equivalents of KBr were added to the Pt(NN)(H2O)22+ solution 
instead of 10 equivalents of LiCl. 
Table 2:30 Colour and yields of the (NN)-bromo complexes of platinum(II) prepared via 
silver method  
Complex Code Yield (%) Colour 
PtBr2(2-picolylamine) Mar9.3 55 Yellow 
PtBr2(mmaei) Mar1.3 73 Yellow 
PtBr2(mmabi) Mar6.3 50 Yellow 
PtBr2(maep) Mar8.3 68 Yellow 
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Table 2:31 Solubility data of the (NN)-bromo complexes of platinum(II) prepared via 
silver method  
Compound Code Solubility (g/l) Solubility (mM) 
Pt(2-picolylamine)Br2 Mar9.3 0.0561 0.121 
Pt(mmaei)Br2 Mar1.3 0.556 1.125 
Pt(mmabi)Br2 Mar6.3 0.174 0.313 
Pt(maep)Br2 Mar8.3 0.0562 0.114 
Table 2:32 Selected infrared data of the (NN)-bromo complexes of platinum(II) prepared 
via the silver method  
Compound C=N str (cm-1) 
C=C ring vib 
(cm-1) 
C=N-C=C ring 
vib (cm-1) 
C-N-C asym str 
(cm-1) 
PtBr2(2-picolylamine) 1616 1579 1489 1114 
PtBr2(mmaei) 1653 1516 1458 1086 
PtBr2(mmabi) 1643 1516 1454 1086 
PtBr2(maep) 1611 1564 1481 1090 
Table 2:33 C, H, N elemental analysis of the (NN)-bromo complexes of platinum(II) 
prepared via the silver method 
Complex 
%C %H %N 
Exp. Calc. Exp. Calc. Exp. Calc. 
PtBr2(2-picolylamine) 15.7 15.6 2.0 1.5 5.9 6.1 
PtBr2(mmaei) 16.6 17.0 2.3 2.7 7.8 8.5 
PtBr2(mmabi) 26.2 26.0 2.8 2.5 7.7 7.6 
PtBr2(maep) 19.8 19.6 2.6 2.5 5.3 5.7 
2.7.3 Oxalato complexes 
The oxalato complexes were synthesized from the appropriate iodo analogues by 
the silver method as described for the synthesis of chloro complexes. In this case, 
however, 1.1 molar equivalents of K2C2O4•2H2O were added to the Pt(NN)(H2O)22+ 
solution instead of 10 equivalents of LiCl. 
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Table 2:34  Colour and yields of the (NN)-oxalato complexes of platinum(II) prepared via 
silver method  
Complex Code Yield (%) Colour 
Pt(C2O4)(2-picolylamine) Mar9.1 71 Pale yellow 
Pt(C2O4) (mmaei) Mar1.1 52 White 
Pt(C2O4) (mmabi) Mar6.1 35 Pale yellow 
Pt(C2O4) (maep) Mar8.1 74 White 
Table 2:35 Solubility data of the (NN)-oxalato complexes of platinum(II) prepared via 
silver method  
Compound Code Solubility (g/l) Solubility (mM) 
Pt(C2O4)(2-picolylamine) Mar9.1 0.594 1.522 
Pt(C2O4) (mmaei) Mar1.1 0.786 1.861 
Pt(C2O4) (mmabi) Mar6.1 0.644 1.332 
Pt(C2O4) (maep) Mar8.1 0.293 0.699 
Table 2:36 Selected infrared data of the (NN)-oxalato complexes of platinum(II) prepared 
via the silver method  
Compound C=N str (cm-1) 
C=C ring vib 
(cm-1) 
C=N-C=C ring 
vib (cm-1) 
C-N-C asym str 
(cm-1) 
PtOx(2-picolylamine) 1609 - 1483(m) 1119 
PtOx(mmaei) 1636 1522 1460 1099 
PtOx(mmabi) 1643 1518 1454 1088 
PtOx(maep) 1630 1518 1468 1107 
Table 2:37 C, H, N elemental analysis of the (NN)-oxalato complexes of platinum(II)  
prepared via the silver method 
Complex 
%C %H %N 
Exp. Calc. Exp. Calc. Exp. Calc. 
Pt(C2O4) (2-picolylamine) 26.4 26.7 2.1 2.5 7.2 6.9 
Pt(C2O4) (mmaei) 25.6 25.6 3.2 3.1 9.7 10.0 
Pt(C2O4) (mmabi) 34.5 34.8 3.2 2.9 8.4 8.7 
Pt(C2O4) (maep) 28.6 28.7 3.1 2.9 6.3 6.7 
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2.8 SYNTHESIS OF PLATINUM(IV) COMPLEXES 
2.8.1 Mononitroplatinum(IV) Complexes 
Pt(NN)(C2O4) (12.7 mmol) was suspended in 100 mL distilled water and 235 mL 
acetone (a 30:70 water:acetone mixture). 1 Molar equivalent (12.7 mmol) of 
sodium chloride was dissolved in 3 mL of distilled water and added to the 
suspension. Nitrogen dioxide gas was bubbled through the solution while stirring 
at room temperature for 1 hour until a green solution was formed. The solution 
was stirred overnight at room temperature, after which the volume of the resultant 
yellow solution was reduced to 120 mL by bubbling nitrogen gas through for 5 
hours. The apparatus used for the oxidation reactions is shown in figure 2.1.  
 
Figure 2:1 Experimental set-up used for the NO2 oxidation reactions 
The suspension was filtered and the precipitate washed four times with 25 mL 
aliquots of water at 40°C and dried overnight in an oven at 50°C. The product was 
re-dissolved in 150 mL acetone and impurities filtered off, after which the solution 
was evaporated to dryness under vacuum. The precipitate thus obtained was 
washed three times with 20 mL aliquots of water at 40°C and dried in an oven at 
N2 Gas
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NO2 Gas
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        HNO3
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50°C overnight. Some detail of the mononitroplatinum(IV) complexes synthesized 
according to this method are given in Table 2.38. 
Table 2:38 Colour and yields of the mononitroplatinum(IV) compounds 
Complex Code Yield (%) Colour 
Pt(C2O4) (2-picolylamine)NO2Cl Mar9.1.4 30.4 Yellow 
Pt(C2O4) (DACH)NO2Cl Mar4.1.4 83.2 Light Yellow 
Pt(C2O4) (NH3)2NO2Cl Mar2.1.4 65.9 Yellow 
 
Table 2.39 C, H, N elemental analysis of mononitroplatinum(IV) complexes 
Complex 
%C %H %N 
Exp. Calc. Exp. Calc. Exp. Calc. 
Pt(C2O4) (2-picolylamine)NO2Cl 20.6 20.4 1.8 1.5 8.7 8.9 
Pt(C2O4) (DACH)NO2Cl · 2H2O 18.7 18.7 3.5 3.5 8.3 8.2 
Pt(C2O4) (NH3)2NO2Cl 6.3 6.0 1.7 1.5 10.6 10.5 
 
2.9 CHEMICALS  
CHEMICAL SUPPLIER 
1-Methyl imidazole  (≥99%)  Fluka 
1R,2R-1,2-diaminocyclohexane  (98%) Aldrich 
2-(Aminomethyl)pyridine Aldrich 
2-(2-Methylaminoethyl)pyridine Aldrich 
25% Ammonium solution Associated Chemical Enterprises(ACE) 
2-Picolyl chloride hydrochloride  (98%) Aldrich 
Acetone  (99%) SMM Chemicals 
Acetonitrile  (99.8%) Riedel-de Haen 
Chloroform  (99%) Unilab 
Dichloromethane AR SMM 
Diethyl ether  (99%) SaArchem 
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Dimethyl formamide  (99%) Minema 
Ethanethiol  (97%) Aldrich 
Ethanol  (95%) Merck 
Ethyl acetate  (≥99%) SMM Instruments 
Formaldehyde 40% ACE 
Hydrochloric acid  (37%) SMM Instruments 
Isopropanol  (99%) Minema 
Lithium chloride anhydrous AR Saarchem 
Methanol  (99.5%) Saarchem 
Nitric acid  (55%) Riedel-de Haen 
Nitrogen  (99.999) Afrox 
Oxalic acid  (99%) Merck 
Perchloric acid  (70%)   ACE 
Platinum metal  (99.9999%) Impala platinum 
Potassium bromide  AR ACE 
Potassium carbonate anhydrous AR SaArchem 
Potassium chloride  AR SaArchem 
Potassium iodide  AR SMM Instruments 
Potassium oxalate monohydrate  (99.5%) Riedel-de Haen 
Propanethiol  (99%) Aldrich 
Silver nitrate  (99%) SaArchem 
Sodium chloride (99.5 %) Minema 
Sodium carbonate anhydrous AR Unilab 
Sodium hydroxide pellets AR Labchem 
Sodium sulphate anhydrous AR ACE 
Sulfur dioxide  (99.9%) Afrox 
Thionyl chloride  (99%) Fluka 
Thiophenol  (98%) Merck-Schuchardt 
Toluene  (99%) SMM Chemicals 
Trans-1,2-diaminocyclohexane  (95%) Fluka 
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CHAPTER 3:   
PLATINUM AND PALLADIUM (NS)-HALO COMPLEXES 
3 INTRODUCTION 
The biological activity of platinum anti-tumour agents is controlled by their complex 
chemical reactions with various biomolecules throughout the body.  It is generally 
accepted that platinum(II) drugs such as cisplatin, cis-PtCl2(NH3)2, when reaching 
the cellular target DNA, form 1,2-intrastrand cross-links with the aromatic nitrogen 
atoms (N7) of the guanine (see structure in figure 3.1)  base which acts as 
cytotoxic adducts.17  A relatively small percentage of the drug, however, reaches 
the target due to the “side reactions” with biochemicals in the blood and normal tissue 
in organs.52
4
  The reactions lower the efficiency of the anticancer action and lead to 
various toxicities, e.g. nephrotoxicity, gastrointestinal toxicity and possible bone 
marrow suppression.   Sulfur-donor molecules like glutathione, cysteine and 
methionine play an important role in these “secondary reactions”.42   This can be 
related to the strong interaction between platinum(II) and the “soft” centres of sulfur 
donors.  These reactions are very complex due to a number of factors of which 
thermodynamic and kinetic factors are probably the most important.                      
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Guanine (G)  
Figure 3:1: Structure of guanine 
Studies regarding relative donicities of sulfur donors suggest that they can be 
divided into two groups with reference to their action on platinum(II) complexes 
namely those with σ donor π donor capabilities like thiols and thiourea.43  These 
ligands react irreversibly with platinum(II).  The second group containing σ donor 
π acceptor S atoms like thioethers, and dimethylsulfoxide is substituted by N7 
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atoms of guanine to give the thermodynamically more stable Pt-nucleobase 
adduct. 
Kinetic factors play an equally important role since in spite of the above 
thermodynamic effect the platination of sulfur donors, e.g. thioethers occur in 2 
hours whereas that of the N7 of guanine takes 15h under comparable conditions.52  
These kinetic differences are likely to play a role in the “protective action” of sulfur 
donors and the possibility of creating a “drug reservoir”.5  
Although progress has been made in understanding the various facets of Pt-S 
interaction regarding their anticancer behaviour the simultaneous equilibria involved 
are numerous and exclusive interpretations are not readily reached.4, 5, 44 
In light of the need for more information regarding the action of S-donor ligands in 
anticancer action of platinum(II) complexes a project was initiated to study the 
properties of platinum(II) complexes of a bidentate ligand having an aromatic N-donor 
atom in combination with a thioethereal S atom capable of forming a five-membered 
ring with platinum(II).  In addition the basic structure should allow substitution to be 
made to change the stereochemistry, hydrophobicity and S-donor strength enabling 
the influence of these parameters to be studied on the outcome of the platinum(II) 
complex species and the anticancer action.  Two structures were planned to achieve 
this namely 2-methylthioalkyl/arylpyridine and  N-alkyl-2-methylthioalkyl/aryl imidazole 
(See Figure 3.2).  The attachment of the –SR group to a potentially electron 
withdrawing group was selected to somewhat weaken the influence of the 
thioethereal sulfur donor capability.  The main emphasis in this dissertation will be on 
the pyridine analogues.  A comparison will then be made between the results 
obtained of the two types of non-leaving groups.  A number of different counterions 
will be studied in view of their possible effects on the ligand exchange rate namely 
different halides and dicarboxylate ions.  
In this research the synthesis of the ligands, their complexes with platinum(II) and 
Pd(II) will be reported as well as other properties relating to potential anticancer 
action.  In this chapter only the halo complexes of the pyridine derivatives will be 
described, discussed and where meaningful compared to those of the imidazole 
derivatives studied in this laboratory.53,54  
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Figure 3:2  (NS)-donor ligands 
Not all the (NS)-ligands used in this dissertation have been studied as complexing 
agents for both platinum(II) and palladium(II). Therefore, the palladium(II) 
complexes were also synthesized and studied to be able to compare the 
coordination chemistry of these two metals.  This has been done although it was 
anticipated that the Pd(II) complexes could not be expected to have significant 
anticancer action because of the faster ligand exchange rates of palladium(II) 
complexes. 
3.1 SYNTHETIC METHODS (THEIR CONTRIBUTION TO THE 
UNDERSTANDING OF THE CHEMISTRY INVOLVED) 
3.1.1 Introduction 
In this paragraph, it will be shown how the application of the two different methods 
described in chapter 2 contributed to the understanding of the chemical processes 
involved.  In chapter 2, the products obtained from the two different methods 
already had in many cases different colours, indicating chemical differences. The 
application of different physical characterization methods will now be investigated 
to illustrate the exact nature of the differences. 
The preparation of the chloro complexes of Pd(II) was performed by the direct 
reaction of the (NS)-ligands in a 1.15:1 mole ratio of K2PdCl4 in aqueous medium 
(method I).55
N
N
R1
where R2 = CH3, C2H5, C3H7, phenyl and benzyl
           R1 = always CH3, but in a few cases = butyl
g      g
CH2SR2
N
CH2SR2
 This method also proved to be successful for the synthesis of 
chloropalladium(II) complexes of diamine ligands.  Initially the analogous method 
was used for the synthesis of the platinum(II) analogues.  Although diamine 
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ligands proved to produce neutral molecular species of the type diamine-bis-
chloroplatinum(II) in some instances, e.g. with dach*,56 however, mixtures 
including auto-ionized species, e.g. [Pt(en)2PtCl4]57
K2PtCl4 + 4I-             K2PtI4              Pt(NS)I2                    Pt(NS)(H2O)22+  +                        Pt(NS)X2     
(X = Cl- or Br-)                 Eq.3.1 
(NS) denotes analogues of pyridine (py) and imidazole as indicated in Figure 3.2.  
The complexes studied will be divided in terms of the structural units of their non-
leaving groups, namely:  
 are obtained in other cases.  
The silver method (method II) (see equation 3.1) was used later when it was 
realized that doubt exists about the purity of the (NS)-platinum(II) complexes 
prepared by method 1.   
1. 2-((methylthio)methyl)pyridine (mtmpy) 
2. 2-((ethylthio)methyl)pyridine (etmpy) 
3. 2-((propylthio)methyl)pyridine (prtmpy) 
4. 2-((phenylthio)methyl)pyridine (phtmpy) 
5. 2-((benzylthio)methyl)pyridine (bzltmpy) 
In order to simplify the notation the code followed is as follows; Mar7.2 refers to 
the dichloride e.g. Pt(mtmpy)Cl2 and Mar7 is used for the dicationic species 
Pt(mtmpy)2+.  Mar7.3 signifies the bromo analogue and Mar7.5 the iodo analogue, 
Mar7.5d refers to the palladium iodo analogue. 
3.2 DIRECT LIGAND EXCHANGE FROM K2PtCl4 
When the direct ligand exchange method (method I) was applied, yellow chloro 
complexes precipitated for Pd(II) whereas those of platinum(II) were very insoluble 
pink to peach-coloured complexes.  The appearance of mass spectral peaks for 
the monomolecular species for the palladium(II) complexes left little doubt.  This 
                                            
* Dach=1,2-diaminocylohexane 
NS 
  2Ag+ + 2NO3- AgI                                                               
X- 
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has been proved by a structural determination of one of them Mar5d.2 (see at the 
end of the chapter) The pink colour of the platinum(II) (NS)-chlorides already 
created suspicion whether these were true monomeric species as a result of the 
red colour of PtCl42- which will be present in the auto-ionized species [Pt(NS)22+, 
PtCl42-].  The common analytical methods namely CHNS, IR spectrophotometric 
analysis could not provide exclusive evidence for these complexes.  Mass spectral 
methods however, could provide some answers.  As explained (Chapter 2) 
different mass spectra were run. FAB was used occasionally, in which case a non-
polar solvent was used. Electrospray was used regularly, in which case a polar 
solvent was used (a CH3CN/H2O mixture). (See Chapter 2).  In the FAB method, 
evidence was obtained for the presence of some monomolecular species, but also 
the presence of some auto-ionized species (see later).  The electrospray mass 
spectral method produced even more explicit evidence of the presence of both 
(monomolecular and auto-ionized).  See e.g. figure 3.16 for the case of Mar16.2.  
In view of these results the direct method for the synthesis of platinum(II) (NS)-
chlorides was terminated.   
3.3 SILVER METHOD (SEE CHAPTER 2) 
This latter observation led to the alteration of our synthetic method for the platinum(II) 
complexes (method II).  Initially, there was some doubt as to whether the ‘silver 
method’ could be expected as a possible outcome, knowing the high affinity of Ag+ for 
sulfur donors.  Since in the formation of the auto-ionized species important factors are 
firstly the extent of the ion pairing between [Pt(NS)2]2+ and [PtX4]2- (X=Cl) and also the 
stabilities of [PtX4]2- which will necessarily differ from Cl- to Br- to I-.  It was thought 
worthwhile to proceed via the iodo complex.  A further indication that the iodo-option 
is advantageous for this purpose was given by the analogous procedure used for the 
synthesis of cisplatin and since it is known that the affinity of Ag+ for I- is much greater 
than for Cl-, thus less likely of Ag+ - S interaction.  This method proved to be very 
successful rendering yellow products of the monomeric species for platinum(II) clearly 
different to the products of method I.   
The physical properties related to the (NS)-complexes will be given and discussed 
here.  Although the infrared spectroscopic studies were expected not to be very 
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informative due to overlap of peaks of characteristic groups, a study was 
nevertheless performed and will be discussed in the next paragraph (3.5) 
3.4 INFRARED SPECTROSCOPIC STUDIES 
The infrared spectra (3800-200 cm-1) of the complexes were measured in the solid 
phase as described in chapter 2.  The complete infrared data of the complexes are 
given in chapter 2, however, some important shifts are given below in Table 3.1. 
Table 3:1 IR shifts for the (NS)-halo complexes 
Complex Code C=N shift (cm-1) CH2-S def shift (cm-1) CH2-S wag shift (cm-1) 
Pt(mtmpy)I2 Mar7.5 18 -43 13 
Pt(mtmpy)Cl2 Mar7.2 26 -37 31 
Pt(mtmpy)Br2 Mar7.3 20 -38 30 
Pt(etmpy)I2 Mar5.5 14 -39 0 
Pt(etmpy)Cl2 Mar5.2 18 -34 4 
Pt(etmpy)Br2 Mar5.3 17 -35 4 
Pt(ptmpy)I2 Mar13.5 15 -36 27 
Pt(ptmpy)Cl2 Mar13.2 17 -35 0 
Pt(ptmpy)Br2 Mar13.3 17 -32 1 
Pt(phtmpy)I2 Mar14.5 19 -49 28 
Pt(phtmpy)Cl2 Mar14.2 20 -39 34 
Pt(phtmpy)Br2 Mar14.3 18 -49 30 
Pt(bztmpy)I2 Mar16.5 26 -41 29 
Pt(bztmpy)Cl2 Mar16.2 17 -35 3 
Pt(bztmpy)Br2 Mar16.3 17 -39 25 
The significant shifts obtained in both the C=N range as well as the CH2-S ranges 
signify metal interaction with the donor atoms.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
3.5 MASS SPECTRAL STUDIES 
C, H, N and S elemental analysis, and even infrared spectral data, cannot readily 
provide exclusive evidence for the nature of the complex species, since the auto-
ionized [Pt(NS)2]2+[PtX4]2- and the molecular species [Pt(NS)X2] have the same 
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percentage analysis of the elements. It was thus decided to depend on mass 
spectral data to provide us with such information. Even this method has a problem 
insofar as that these platinum complexes have highly covalent character 
increasing in the direction from chloro to iodo complexes. The compounds are not 
soluble in non-polar solvents, and when dissolved in polar solvents ionization 
occurs, to a greater or lesser extent, depending on the nature of the complex 
(chloro, bromo or iodo) and the nature of the solvent. 
In spite of this however, it is still possible to determine the nature and constitution of 
the complex and whether impurities are present. The presence of some ionized 
species which originate from the molecular species and the absence of any other 
material is still a good indication of the purity of the complex in conjunction with the 
other analytical data. 
The interpretation of the results from the electrospray mass spectral-data (solution 
data) appears to be even more trustworthy when the results of the FAB mass 
spectral method (solid state) showed that only the molecular species are present. 
A typical example of the FAB spectra has been given in figure 3.3. 
                                                           m/z 
Figure 3:3 FAB mass spectrum of J5.2 [PtCl2(1-methyl-2-methylthioethylimidazole)] 
The electrospray mass spectral data of the platinum complexes will now be 
discussed for each non-leaving group, starting with those of the S-methyl ligand. 
These are Mar7.5 (iodo), Mar7.3 (bromo) and Mar7.2 (chloro). For the latter, the 
spectra for both the direct and indirect synthetic methods will be discussed. 
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3.5.1 Mar7 complexes  [Pt(mtmpy)X2] (S-methyl)  
(i) Mar7.5 (iodo complex) 
The iodo complex will be discussed first, since this was the starting material for all 
the others. The iodo complexes in general could be prepared in a high yield, due 
to their low aqueous solubility, and under careful experimental conditions a high 
degree of purity could be achieved. The mass spectra obtained by the 
electrospray method in a mixture of methyl cyanide and water are given in figure 
3.4. The top spectrum represents results obtained in the positive mode whereas 
the bottom spectrum represents those of the negative mode. The formulae of the 
identified species are given below the spectra. 
The major peaks in the positive mode are those of the monocationic species in 
two solvated forms – as a methyl cyanide adduct and an aqua adduct. In the 
negative ion mode, the molecular species is indicated (586 [M-H+]-). 
The data thus suggest that an equilibrium exists between the molecular and the 
monocationic ionized species. There is, however, virtually no evidence of any 
contaminants. The mass spectral behaviour obtained under these conditions is 
typical for the iodo complexes with reference to their purity. 
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Possible structures of detected ions 
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Figure 3:4 Full scan mass spectrum of sample Mar7.5 in MeCN/H2O solution for positive 
ion (top) and negative ion mode (bottom) and structures of species observed 
(below) 
(ii) Mar7.3 (bromo complex) 
The mass spectra of Mar7.3 are represented by figure 3.5. In the positive ion 
mode there is only evidence for the monocationic species (430 [M-Br+H2O]+ and 
456 [M-Br+CH3CN]+). In the negative ion mode, the major peak is also for a specie 
in which one bromide is lost (458 [M-HBr+HCOO]-), and a small peak for the 
molecular species. 
There are two noticeable differences between the behaviour of the iodo and 
bromo species. Firstly, the methyl cyanide solvate is the major species in the case 
of the iodo complex, whereas the aqua-solvate is the major species for the bromo 
complex. Secondly, the percentage ionization seems to be much higher in the 
case of the bromo species, where only a very small peak indicates the presence of 
the molecular species (490 [M-H]- in the negative ion mode). 
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Figure 3:5  Full scan mass spectrum of sample Mar7.3 in MeCN/H2O solution for positive 
ion (top) and negative ion mode (bottom) and structures of species observed 
(below) 
(iii) Mar7.2 (chloro complex) 
The mass spectra of Mar7.2 as obtained from the silver method are given in figure 
3.6. These spectra correspond very closely to those obtained from the bromo 
complex, not only with respect to the type of species but even in terms of their 
relative abundance. The monocationic species again are the most common and 
some evidence is seen for the molecular species, but very little for the dicationic 
species. 
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Figure 3:6  Full scan mass spectrum of sample Mar7.2 (silver method) in MeCN/H2O 
solution for positive ion (top) and negative ion mode (bottom) and structures 
of species observed (below) 
3.5.2 Mar5 complexes  [Pt(etmpy)X2] (S-ethyl) 
(i) Mar5.5 (iodo complex) 
The mass spectra of Mar5.5 are given in figure 3.7. The spectrum obtained in the 
positive ion mode suggests a very small amount of molecular species and almost 
equal amounts of monocationic and dicationic ionized species. This conclusion rests 
on the assumption that the molar extinctions of the different ionized species do not 
differ significantly. This is surprisingly different from the behaviour of the S-methyl 
derivative (Mar7.5) which indicated a small amount of ionization under similar 
conditions. The presence of a small percentage of the auto-ionized species is also 
indicated in the positive ion mode (627 [ML2I]).  In the negative ion mode, the major 
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species is the molecular species (600 [M-H]). 
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Figure 3:7  Full scan mass spectrum of sample Mar5.5 in MeCN/H2O solution for positive 
ion (top) and negative ion mode (bottom) and structures of species observed 
(below) 
(ii) Mar5.3 (bromo complex) 
In the positive ion mode, virtually no evidence of the molecular species is seen, 
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only monocationic and a large amount of dicationic species are indicated. This 
behaviour therefore agrees with that of the iodo analogue.  
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Figure 3:8 Full scan mass spectrum of sample Mar5.3 in MeCN/H2O solution for positive 
ion (top) and negative ion mode (bottom) and structures of species observed 
(below) 
 
(iii) Mar5.2 (chloro complex) 
The mass spectra obtained from the product synthesized by the direct method 
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gave a number of unidentified peaks, whereas those from the silver method 
suggest a pure compound (see figure 3.9). This result is surprising insofar as the 
extent of the ionization is limited when compared to the behaviour of the bromo 
and iodo analogues. 
 
Possible structures of detected ions 
N
S CH3
Cl
Cl
Pt
NH4
+
435+
N
S CH3
Pt
+
N
N
S CH3
ClPt
CH3
400+ 423+ 346+
OH2
N
S CH3
ClPt
 
N
S CH3
Cl
Cl
Pt
-
416-  
Figure 3:9  Full scan mass spectrum of sample Mar5.2 (silver method) in MeCN/H2O 
solution for positive ion (top) and negative ion mode (bottom) and structures 
of species observed (below) 
3.5.3 Mar13 complexes  [Pt(prtmpy)X2] (S-propyl) 
    (i)    Mar13.5 (iodo complex) 
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The mass spectra of Mar13.5 are represented by figure 3.10. In the positive ion 
mode there is clear evidence for almost an even distribution between the 
molecular, monocationic and dicationic forms. In the negative ion mode there is 
evidence for the molecular as well as the dealkylated form resulting in a negatively 
charged sulphur atom.  This behaviour is different from both the S-methyl (Mar7.5 
– no dicationic species) (compare figure 3.4) and the S-ethyl (Mar5.5 – very little 
evidence of molecular species and large dicationic presence) (compare figure 
3.7). 
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Figure 3:10  Full scan mass spectrum of sample Mar13.5 in MeCN/H2O solution for 
positive ion (top) and negative ion mode (bottom) and structures of species 
observed (below) 
       (ii) Mar13.3 (bromo complex) 
The mass spectra of the bromo analogue (Mar13.3) are represented in figure 
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3.11. These spectra correspond well with those of its iodo analogue (figure 
3.10). 
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Figure 3:11  Full scan mass spectrum of sample Mar13.3 in MeCN/H2O solution for 
positive ion (top) and negative ion mode (bottom) and structures of species 
observed (below) 
(iii)      Mar13.2 (chloro complex) 
The mass spectra of Mar13.2 obtained by the direct method (shown in figure 3.12) 
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have indications of the presence of both molecular and auto-ionized species. The 
spectra obtained from the silver method (figure 3.13) indicate a relatively small 
amount of ionization (monocationic and dicationic species), while the molecular 
species are clearly in the majority. 
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Figure 3:12  Full scan mass spectrum of sample Mar13.2 (direct method) in MeCN/H2O 
solution for positive ion (top) and negative ion mode (bottom) and structures 
of species observed (below) 
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Figure 3:13  Full scan mass spectrum of sample Mar13.2 (silver method) in MeCN/H2O  
solution for positive ion (top) and negative ion mode (bottom) and structures 
of species observed (below) 
This behaviour corresponds with that of Mar5.2 but differs from that of Mar7.2. 
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3.5.4 Mar16 complexes  [Pt(bzltmpy)X2) (S-benzyl) 
(i) Mar16.5 (iodo complex) 
The mass spectral data of the iodo complex of the S-benzyl ligand (i.e. Mar16.5) 
are shown in figure 3.14. The spectra obtained in the positive ion mode indicates 
the presence of all three possible molecules – the molecular, monocationic and 
dicationic species, the latter being the most prominent. Those of the negative ion 
mode indicate mainly the molecular species. 
 
Figure 3:14  Full scan mass spectrum of sample Mar16.5 in MeCN/H2O solution for 
positive ion (top) and negative ion mode (bottom) and structures of species 
observed (below) 
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(ii) Mar16.3 (bromo complex) 
The mass spectra given in figure 3.15 are similar to those of the iodo species. 
However, indications of a larger extent of ionization are present. 
 
   
Figure 3:15  Full scan mass spectrum of sample Mar16.3 in MeCN/H2O solution for 
positive ion (top) and negative ion mode (bottom) and structures of species 
observed (below) 
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(iii) Mar16.2 (chloro complex) 
The mass spectra of the Mar16.2 obtained by the direct method (figure 3.16) are 
clearly more complicated than the similar spectra obtained from the Mar16.2 
prepared by the silver method (figure 3.17) and indicates the presence of auto-
ionized species. The spectrum of the latter has only evidence for the molecular 
species and some dicationic. 
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Figure 3:16  Full scan mass spectrum of sample Mar16.2 (direct method) in MeCN/H2O 
solution for positive ion (top) and negative ion mode (bottom) and structures 
of species observed (below) 
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Figure 3:17  Full scan mass spectrum of sample Mar16.2 (silver method) in MeCN/H2O 
solution for positive ion (top) and negative ion mode (bottom) and structures 
of species observed (below) 
3.5.5 Mar14 complexes  [Pt(phtmpy)X2] (S-phenyl) 
     (i) Mar14.5 (iodo complex) 
The mass spectra of the iodo complex of the S-phenyl non-leaving group 
(Mar14.5) are given in figure 3.18. The major peaks in the positive ion mode 
indicate monocationic and dicationic species with a very small presence of 
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unionized. In the negative ion mode there is some indication for the molecular 
species. 
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Figure 3:18 Full scan mass spectrum of sample Mar14.5 in MeCN/H2O solution for 
positive ion (top) and negative ion mode (bottom) and structures of species 
observed (below) 
(ii) Mar14.3 (bromo complex) 
These spectra (figure 3.19) are similar to those of the iodo analogue, the main 
species being monocationic with small amounts of dicationic and molecular 
species. The negative ion mode again shows the presence of molecular species. 
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Figure 3:19 Full scan mass spectrum of sample Mar14.3 in MeCN/H2O solution for 
positive ion (top) and negative ion mode (bottom) and structures of species 
observed (below) 
(iii) Mar14.2 (chloro complex) 
The mass spectra of Mar14.2 obtained by the direct method are shown in figure 
3.20. The spectrum in the positive ion mode indicates the presence of a mixture of 
species, whereas that obtained from the silver method (Figure 3.21) indicates the 
molecular form as the major species with some monocationic and very little 
dicationic species. 
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Figure 3:20  Full scan mass spectrum of sample Mar14.2 (direct method) in MeCN/H2O 
solution for positive ion (top) and negative ion mode (bottom) and structures 
of species observed (below) 
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Figure 3:21  Full scan mass spectrum of sample Mar14.2 (silver method) in MeCN/H2O 
solution for positive ion (top) and negative ion mode (bottom) and structures 
of species observed (below) 
3.5.6 Some concluding remarks 
The ionization of Mar7.2 (the chloride of S-methyl non-leaving group) is clearly 
different to the others since the only species in solution is the monocationic 
species whereas with all the others a distribution is formed between the molecular, 
monocationic and dicationic species. 
It is of interest that the behaviour of the S-methyl imidazole analogue, namely the 
2-methylthiomethylimidazole non-leaving group, which was also studied in this 
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laboratory 53 behaves similarly to the S-methyl-analogue of the pyridine complex 
(Mar7.2). This apparent abnormality could not readily be explained by the 
available data. 
Since the mass spectral studies were performed in a mixed methyl cyanide / water 
solvent system in order to compare the different halo analogues (the iodo 
complexes were only marginally soluble in water). The results obtained at best 
tells us something about the coordination behaviour of the complexes, but have 
little relation to anticancer action since the presence of methyl cyanide has a major 
influence especially in relation to its solvation of the iodo species. 
3.6 MOLECULAR MODELLING  
It was decided to perform molecular modelling studies on these complexes to 
obtain more information regarding the structures of these complexes, in an effort 
to better understand their anticancer activity. This was accomplished by the use of 
a molecular modelling software package (SPARTAN ’04).  Energy–minimized 
molecular models (calculated via a semi-empirical, PM3 approach) of all the 
compounds were done. The additional information obtained by applying this 
method was very limited and the ball-and-stick models of a few prototypes are 
shown in the following figures.     
                              
(a)                                                                            (b) 
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                                  (c)                                                                       (d) 
Figure 3:22 Ball-and-stick models of the (NS)-iodo complexes (a) Mar7.5 (b) Mar5.5 (c) 
Mar13.5 and (d) Mar14.5  
                                 
(a)                                                                    (b) 
                                                                      
                    (c)                                                                         (d) 
Figure 3:23 Ball-and-stick models of the (NS)-chloro complexes (a) Mar7.2 (b) Mar5.2 (c) 
Mar13.2 and (d) Mar14.2                                                                                                                              
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(a) (b) 
                                             
                                   (c)                                                                            (d) 
Figure 3:24 Ball-and-stick models of the (NS)-bromo complexes (a) Mar7.3 (b) Mar5.3 (c) 
Mar13.3 and (d) Mar14.3  
3.7 ANTICANCER TESTING  
The percentage inhibition of the (NS)-halo complexes on the growth of three 
different cancer cell lines were tested and are shown in the following tables.  
Complexes with significant anticancer potential are indicated in red, whereas 
those with poor anticancer activity are shown in black. 
3.7.1 Cervical cancer (HeLa) 
The data for cervical cancer are given in table 3.2. The chloro and bromo 
complexes of Mar7 (2-methylthiomethylpyridine ligand) are moderately successful, 
especially at their higher concentrations. This also applies to the chloro species of 
the S-ethyl analogue (Mar5.2). Similar results were also obtained from the 
S-phenyl chloro and bromo species (Mar14.2 and Mar14.3) as well as the bromo 
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complex of the S-benzyl analogue (Mar16.3). 
Table 3:2 Cell growth inhibition assay results of (NS)-halo complexes on cervical 
cancer cell lines (HeLa) 
 % Inhibition STD dev 
Conc 
(µM) 
% Inhibition STD dev 
Conc 
(µM) 
Cisplatin 21 54 11 62 1 114 
Mar7.2 17 2 2 49 4 19 
Mar7.3 29 13 1 48 6 13 
Mar5.2 2 3 8 44 4 76 
Mar5.3 0 2 5 3 5 48 
Mar13.2 13 6 7 10 2 69 
Mar13.3 3 7 3 0 4 27 
Mar14.2 0 5 1 31 5 7 
Mar14.3 9 1 1 48 2 10 
Mar16.2 5 8 1 4 7 9 
Mar16.3 8 9 1 32 2 10 
3.7.2 Colon cancer (HT29) 
The results shown in table 3.3 clearly illustrate the inefficiency of the 
(NS)-halopyridine complexes for the treatment of colon cancer. 
Table 3:3 Cell growth inhibition assay results of the (NS)-halo complexes on colon 
cancer cell lines (HT29) 
 % Inhibition STD dev 
Conc 
(µM) 
% Inhibition STD dev 
Conc 
(µM) 
Cisplatin 45 3 11 64 1 114 
Mar7.2 8 10 2 9 6 19 
Mar7.3 14 5 1 10 2 13 
Mar5.2 1 7 8 6 9 76 
Mar5.3 10 3 5 2 2 48 
Mar13.2 24 2 7 14 2 69 
Mar13.3 5 5 3 0 16 27 
Mar14.2 8 3 1 0 1 7 
Mar14.3 0 6 1 12 7 10 
Mar16.2 4 2 1 1 5 9 
Mar16.3 0 5 1 5 3 10 
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3.7.3 Breast cancer (MCF7) 
The data for breast cancer are given in table 3.4. In this instance, there is a 
resemblance in the behaviour of structural groups in terms of their efficiency, e.g. 
Mar7.2, Mar7.3, Mar5.2, Mar14.2, Mar14.3 and Mar16.3 have similar efficiencies 
as observed in the case of cervical cancer. In this case only, Mar5.3 also has 
improved behaviour. 
Table 3:4 Cell growth inhibition assay results of the (NS)-halo complexes on breast 
cancer cell lines (MCF7) 
 % Inhibition 
STD 
dev 
Conc 
(µM) 
% Inhibition 
STD 
dev 
Conc 
(µM) 
Cisplatin 39 1 11 65 1 114 
Mar7.2 13 3 2 49 5 19 
Mar7.3 23 7 1 55 4 13 
Mar5.2 7 6 8 56 3 76 
Mar5.3 19 8 5 48 5 48 
Mar13.2 9 6 7 10 7 69 
Mar13.3 0 8 3 13 12 27 
Mar14.2 11 3 1 38 6 7 
Mar14.3 19 6 1 58 1 10 
Mar16.2 2 5 1 0 7 9 
Mar16.3 0 7 1 35 4 10 
When considering the above results, there seems to be a correlation between the 
anticancer behaviour and the structural superposition of the neutral ligand (non-
leaving group). 
3.8 IONIZATION RATES 
Ionization studies on these complexes in acetonitrile and in aqueous solution 
where possible showed that their ionization rates are very fast, resulting rapidly in 
cationic solvated species. As a result, satisfactory ionization curves could not be 
obtained. This behaviour can be correlated with the trans effect of the sulfur-
donor.  A full X-ray structural determination of the (NS)-imidazole analogue of 
Mar5.2 showed that the Pt-Cl bond distance to the Cl atom trans to the sulfur atom 
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is 2.3246(12) Å as compared to the Pt-Cl distance for the Cl atom trans to the N-
donor atom of 2.3027(11) Å. This emphasizes the large trans effect obtained. The 
difference in Pt-Cl bond length is 0.0219 Å 58
 
. A similar difference in bond distance 
of the palladium analogue was obtained, namely 0.0321 Å. 
The results of the analogous oxalato complexes are discussed in the next chapter. 
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CHAPTER 4: 
(NS)-OXALATO PLATINUM COMPLEXES 
4 INTRODUCTION 
A study of the oxalato complexes of the (NS)ligands was deemed relevant since 
the difference in extent of ionization of the platinum(II) chloro complexes such as 
cisplatin as compared to their dicarboxylato analogues (oxaliplatin and 
carboplatin) is well known.  It is also known that the slower ionization rate of the 
latter contributes towards their reduced toxic side effects. In the case of the 
(NS)-complexes, however, where the trans effect of the sulfur atom was clearly 
illustrated in chapter 3, it was of interest to determine to what extent this effect will 
influence the ionization of their oxalato complexes. 
In the case where their ionization can be slowed down similarly to the diamine-
complexes, the (NS)-oxalatoplatinum(II) species will have a better chance to be 
efficient as anticancer agents. 
In light of the above, the oxalato complexes of the (NS)-ligands used in the 
previous chapter were synthesized from their iodo analogues (see chapter 2) and 
studied. In general, the yields obtained for the oxalato species were not as high as 
for the halo analogues, since these are more water-soluble. However, they could 
be obtained in a high degree of purity. 
4.1 INFRARED SPECTROSCOPIC STUDIES 
The infrared spectra (3800-200 cm-1) of the complexes were measured in the solid 
phase as described in chapter 2.  The complete infrared data of the complexes are 
given in chapter 2; however, some important shifts are given below in Table 4.1. 
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Table 4:1 IR shifts for (NS)-oxalato complexes 
Complex Code CH2-S def shift (cm-1) CH2-S wag shift (cm-1) 
Pt(mtmpy)Ox Mar7.1 -11 
 
30 
 Pt(etmpy)Ox Mar5.1 
-16 
 
1 
Pt(prtmpy)Ox Mar13.1 -58 
 
17 
Pt(phtmpy)Ox Mar14.1 -75 
 
30 
Pt(bzltmpy)Ox Mar16.1 -16 
 
29 
The C=N shift could not be assigned easily in the case of the oxalato species due 
to interference of the C=O stretch frequency. 
4.2 MASS SPECTRAL STUDIES 
Mass spectral studies again proved to be very informative with reference to the 
identity and purity of these oxalato species. These spectra will now be given and 
individually discussed with reference to their non-leaving groups. 
4.2.1 Mar7.1 [Pt(C2O4)(mtmpy)] 
The mass spectra of Mar7.1 are given in figure 4.1. The spectrum obtained in the 
positive ion mode suggests a very low extent of ionization since the molecular 
species is the only prominent species. In the negative ion mode, the major species 
is again the molecular species although a demethylated anionic species is also 
present. 
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Figure 4:1 Full scan mass spectrum of sample Mar7.1 in MeCN/H2O solution for positive 
ion (top) and negative ion mode (bottom) and structures of species observed 
(below) 
The high extent of purity obtained in the case of Mar7.1 is clearly illustrated by the 
chromatogram shown in figure 4.2. In the cases of the halo complexes, such 
almost perfect chromatograms could not have been obtained due to the large 
degree of ionization. In the case of Mar7.1, it is thus emphasizing that virtually no 
ionization occurs. 
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Figure 4:2 Chromatogram of Mar7.1 indicating 97.4 % purity 
4.2.2 Mar5.1[Pt(C2O4)(etmpy)] 
The mass spectra of Mar5.1 are shown in figure 4.3. In the spectrum obtained in 
the positive ion mode, the molecular species is by far the dominant species. In the 
negative ion mode, the molecular species is again by far the major species. There 
is again, however, some indication of a dealkylated species.  
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Possible structures of detected ions 
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Figure 4:3 Full scan mass spectrum of sample Mar5.1 in MeCN/H2O solution for positive 
ion (top) and negative ion mode (bottom) and structures of species observed 
(below) 
A very high degree of purity could be obtained in the case of Mar5.1 as indicated 
by the chromatogram in figure 4.4. 
 
Figure 4:4 Chromatogram of Mar5.1 indicating 100 % purity 
4.2.3 Mar13.1 [Pt(C2O4)(prtmpy)] 
The mass spectra of Mar13.1 are given in figure 4.5. Very little evidence of 
ionization is seen in the positive as well as the negative ion mode.  
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Figure 4:5 Full scan mass spectrum of sample Mar13.1 in MeCN/H2O solution for 
positive ion (top) and negative ion mode (bottom) and structures of species 
observed (below) 
A purity of 98 % is indicated by the chromatogram in figure 4.6. 
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Figure 4:6  Chromatogram of Mar13.1 indicating 98 % purity 
4.2.4 Mar16.1 [Pt(C2O4)(bzltmpy)] 
The mass spectra of Mar16.1 are shown in figure 4.7. The major species is once 
again the molecular species, but in this case ionization takes place to a larger 
extent, as shown by the more prominent [M-2X+H2O]2+ peak in the positive ion 
mode spectrum. In the negative ion mode, a significant debenzylation peak is 
indicated. 
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# Name  Time [Min] Height [mAU] Area [mAU.Min] Area [%] RT Offset [Min]  
1 UNKNOWN 4.88  15.2  2.0  2.018 0.00  
2 Mar13.1  6.13  575.2  96.0  97.982 0.00  
        
Total     590.3  98.0  100.000 
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Figure 4:7 Full scan mass spectrum of sample Mar16.1 in MeCN/H2O solution for 
positive ion (top) and negative ion mode (bottom) and structures of species 
observed (below) 
4.2.5 Mar14.1 [Pt(C2O4)(phtmpy)] 
The mass spectra of the complex Mar14.1 are shown in figure 4.8. The spectra in 
both the positive and negative ion mode indicate the presence of a stable 
molecular ion. The exceptional stability of the molecular species in this instance 
can be related to the greater π-interaction between the aromatic ring, S atom and 
the platinum(II) atom. This leads to a higher covalent interaction and almost 
certainly increased bond strength. 
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Possible structures of detected ions   
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Figure 4:8 Full scan mass spectrum of sample Mar14.1 in MeCN/H2O solution for 
positive ion (top) and negative ion mode (bottom) and structures of species 
observed (below) 
In all these oxalato species, the very small extent of ionization is remarkable when 
compared to the large extent of ionization of their halo analogues. It therefore 
seems as if the trans effect of the sulfur is not large enough to counter the 
stabilization of the chelate effect operative in these dicarboxylic species. 
4.3 MOLECULAR MODELLING 
It was decided to perform molecular modelling studies on these complexes to 
obtain more information regarding the structures of these complexes, in an effort 
to better understand their anticancer activity. This was accomplished by the use of 
a molecular modelling software package (SPARTAN ’04).  Energy–minimized 
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molecular models (calculated via a semi-empirical, PM3 approach) of all the 
compounds were done.  The ball-and-stick models of the structures of the 
(NS)-oxalatoplatinum(II) complexes are shown in figure 4.9. 
                              
(a)  (b) 
                                 
                          (c)                                                                      (d) 
Figure 4:9 Ball-and-stick models of (a) Mar7.1 (b) Mar5.1 (c) Mar13.1 and (d) Mar14.1  
4.4 ANTICANCER TESTING  
The percentage inhibition of the (NS)-oxalato complexes on the growth of three 
different cancer cell lines were tested and are shown in the following tables.  
Complexes with significant anticancer potential are indicated in red, whereas 
those with poor anticancer activity are shown in black. 
4.4.1 Cervical cancer (HeLa) 
The data for cervical cancer are given in table 4.2. 
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Table 4:2  Cell growth inhibition assay results of (NS)-oxalato complexes on cervical 
cancer cell lines (HeLa) 
 % Inhibition STD dev 
Conc 
(µM) % Inhibition 
STD 
dev 
Conc 
(µM) 
Cisplatin 21 54 11 62 1 114 
Mar7.1 11 10 2 37 3 20 
Mar5.1 10 4 7 11 2 65 
Mar13.1 12 4 7 16 11 69 
Mar14.1 1 6 4 1 6 43 
Mar16.1 17 4 6 23 9 61 
 
4.4.2 Colon cancer (HT29) 
The data for colon cancer are given in table 4.3. 
Table 4:3 Cell growth inhibition assay results of (NS)-oxalato complexes on colon 
cancer cell lines (HT29) 
 
4.4.3 Breast cancer (MCF7) 
The data for breast cancer are given in table 4.4. 
 
% 
Inhibition 
STD dev 
Conc. 
(µM( 
% 
Inhibition 
STD dev 
Conc 
(µM) 
Cisplatin 45 3 11 64 1 114 
Mar7.1 8 4 2 2 5 20 
Mar5.1 19 3 7 2 9 65 
Mar13.1 31 16 7 33 8 69 
Mar14.1 0 3 4 0 4 43 
Mar16.1 18 9 6 5 7 61 
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Table 4:4 Cell growth inhibition assay results of (NS)-oxalato complexes on breast       
cancer cell lines (MCF7) 
 
% 
Inhibition 
STD dev 
Conc 
(µM) 
% 
Inhibition 
STD dev 
Conc 
(µM) 
Cisplatin 39 1 11 65 1 114 
Mar7.1 8 9 2 30 10 20 
Mar5.1 2 8 7 12 11 65 
Mar13.1 0 13 7 6 6 69 
Mar14.1 0 5 4 10 7 43 
Mar16.1 8 10 6 17 7 61 
The above results show that these (NS)-oxalatopyridine complexes reveal little 
promise for application as anticancer agents for the cancer cells tested. Similar 
results have been obtained with the (NS)-oxalatoimidazole species, except that 
one of them (J7.1 – the imidazole S-methyl analogue) proved to be very 
successful. 
When the very dramatic trans effect of the halo complexes of these (NS)-ligands is 
considered, it is very surprising that the trans effect seems to be totally absent in 
the case of their oxalato analogues. The latter have degrees of ionization 
comparable with those of diamine complexes which is particularly low. 
 
 
 
 
 
 
 
 
92 
CHAPTER 5:    
NEW DEVELOPMENTS OF AMINE COMPLEXES OF 
PLATINUM(II) 
5 INTRODUCTION 
The accidental discovery of the anticancer capability of cis-
diamminedichloroplatinum(II) (cisplatin) in 1965 by Rosenberg led to a 
greatly increased interest in the properties of such complexes. 
Consequently, numerous analogous complexes were synthesized and 
investigated. Most of these cisplatin analogues were chloro complexes, the 
main reason perhaps being the bio-friendly nature of chloride as illustrated 
by its presence of 0.1 M NaCl in serum. Only a few of these complexes, 
however, have entered in clinical trials. Worldwide only three of these, 
namely cisplatin, carboplatin and oxaliplatin are universally applied. See 
figure 5.1 for the structures of the abovementioned anticancer agents. 
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Figure 5:1  Structures of some common platinum anticancer agents 
There are a number of shortcomings of cisplatin, with reference to its efficiency as 
antitumour agent. These are related to the negative secondary effects observed in 
the body, e.g. nausea, ear damage, kidney toxicity, etc. Research directed 
towards improving the efficiency of platinum anticancer-agents was therefore 
strongly motivated. 
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It is essential to understand the mechanism by which these agents operate and to 
investigate further parameters which can increase the efficiency of these 
compounds. In a recent review, some of these efforts which are likely to lead to 
more successful action, were recorded. Factors which could possibly improve 
efficiency will be discussed in the following paragraphs, as well as efforts directed 
in this dissertation towards improving the function of such platinum compounds. 
5.1.1 Factors Influencing efficiency of antitumour action 
5.1.1.1 Ligand exchange rates 
(i)      Halo complexes 
The rate of ligand exchange was soon discovered to be of critical importance for 
successful antitumour action. The generally accepted mode of operation of 
cisplatin can be used to illustrate this action. The first step in the mechanism is 
considered to be aquation (see equation 5.1). 
   Pt(NH3)2Cl2    +    H2O                             Pt(NH3)2Cl(H2O)+    +    Cl-        Eq. 5.1 
The latter platinum species then reacts with donor-atoms in the biological system, 
e.g. sulfurs or nitrogens, in an irreversible fashion. If these atoms belong to the 
DNA of the cancer cell it can lead to apoptosis (cell death). However, if these 
donor-atoms belong to important bio-products it leads to negative secondary 
effects. It is also known that the main mechanism of ligand exchange involves an 
intermediary distorted square-pyramidal activated state (Chapter 1). In the 
presence of small neutral ligands such as ammonia, the platinum atom is 
subsequently rendered “open” to attack, leading to a fast ligand exchange rate, 
which means that only a small percentage of the agent (~30%) reaches the cancer 
cell unaltered. This is the main disadvantage of cisplatin. 
Although some ionization of the platinum(II) compound is required, in the case of 
the bis-chlorodiamineplatinum(II) complexes, this rate and percentage ionization is 
relatively high, which renders these compounds somewhat too reactive, which 
results in the large number of side effects and relatively small percentage of active 
reagent reaching the cancer cells. 
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The ligand exchange rate can be controlled by a number of factors which will now 
be discussed. It was noted in chapter 1 that for neutral platinum(II) complexes 
consisting of two neutral ligands and two anionic ligands, the latter are normally 
the ones which are the so-called “leaving groups” through ionization in the polar 
medium (water). Historically, chloride was the common anionic species (cisplatin). 
In such cases, therefore, the reactivity of the anticancer agent relates mainly to the 
ionization rate of the chloride. By changing the halogen from chloride to bromide to 
iodide, the exchange rates become slower in aqueous solution (thus also serum), 
mainly because of the increase in covalent character of the platinum-halide bond. 
Iodo complexes are known to be very poor anticancer agents, however, it is 
known that in some cases the bromo analogues are better than the chloro 
analogues. The bromo complexes, however, received very little attention in the 
literature. In view of this, it was useful to compare the behaviour of bromo 
complexes to that of their chloro analogues. 
The activation energy for the ionization of the chloro species can also be 
increased by using more bulky non-leaving groups as co-ligands. A typical 
example of this behaviour is found for cis-amminedichloro(2-
methylpyridine)platinum(II) (picoplatin, also labeled ZD0473). This compound has 
a slower ionization rate than cisplatin and cancer cells have lower resistance to 
ZD0473. It is known that detoxification by elevated glutathione levels is one of the 
mechanisms of resistance. This complex, thus, although slower to ionize, reaches 
the same level of platination and lesser detoxification by S-containing 
biomolecules. Another advantage of slower ionization is that lesser negative 
effects occur in the blood where the chloride concentration is 100 µM which gives 
more time for the compound to reach the cancer cell which has a much lower 
chloride ion concentration and thus more rapid formation of the active aqua 
species. 
(ii)      Dicarboxylato complexes 
Two dicarboxylato-complexes are presently on the world market (carboplatin and 
oxaliplatin). One reason for their success is the fact that the chelate action of 
these anions provide enhanced stability, also with reference to kinetics. It is known 
that their ligand exchange rate is only a fraction of those of chloro complexes. This 
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is thus also an important method to increase efficiency of anticancer agents. In the 
present study, therefore, the oxalato analogues of the non-leaving groups of the 
platinum(II) complexes were also synthesized and investigated. The oxalato group 
as a ligand is preferred since the five-membered ring formed with platinum(II) is 
more stable than, for example, the six-membered ring of the malonato group. A 
further positive effect of these is that a smaller amount of non-haematological 
toxicity is observed upon their application. 
(iii)      Platinum(IV) Complexes 
It is also known from basic coordination chemistry that the octahedral 5d6 system 
is more kinetically stable (EAN rule) and since only the SN1 mechanism is viable 
for ligand exchange, this leads to a further increase in kinetic stability. When 
compared to the square planar d8 system with not only lower covalent character 
but also one relatively low-lying orbital, thus both SN1 and SN2 mechanisms are 
feasible. A successful platinum(IV) antitumour-agent has the additional advantage 
that it can be taken orally, as compared to the intravenous application of 
platinum(II) compounds. One such compound, namely cis,trans-
[PtCl2(OAc)2(NH3)cyclohexylamine] (satraplatin, also known as JM216) is a good 
illustration of this type. Platinum(IV) complexes are thus also investigated in this 
research project. 
5.1.1.2 Structure of non-leaving groups 
In the previous section an example was given to illustrate how stereochemistry 
can be applied to slow down ionization. In the same process, an increased 
specificity results, since attack from unwanted biomolecules (e.g. those containing 
the bulky S-donor atom) is also affected. These are the main culprits in causing 
negative effects. Thus screening of the platinum leads to a higher degree of 
platination of the N7 atoms of guanine. It is further known that non-leaving groups 
with a tail end at ~90º to the coordination plane like the trans-(1R,2R)-(-)-1,2-
diaminocyclohexane (DACH) ligand also has a positive interaction towards fixing 
to the DNA during platination.59 More bulky organic attachments normally lead to 
lesser aqueous solubility of the particular complex, but this can be countered by 
employing the oxalato complex which, with its two uncoordinated carbonyl 
96 
oxygens, leads to increased aqueous solubility. This is illustrated by the lower 
aqueous solubility of the Pt(dach)Cl2 as compared to the more soluble 
oxalato(dach)platinum(II) (oxaliplatin). 
5.2 INFRARED SPECTROSCOPIC STUDIES 
The infrared spectra (3800-200 cm-1) of the complexes were measured in the solid 
phase as described in chapter 2. The complete infrared data of the complexes are 
given in chapter 2, however, some important shifts are given below in table 5.1. 
Table 5:1 IR shifts for (NN)-platinum(II) complexes 
Complex Code C=N shift 
(cm-1) 
C=C shift   
(cm-1) 
C=N-C=C 
shift (cm-1) 
C-N-C shift 
(cm-1) 
Pt(2-picolylamine)I2 Mar9.5 5 -10 12 17 
Pt(2-picolylamine)Cl2 Mar9.2 8 -10 16 23 
Pt(2-picolylamine)Br2 Mar9.3 7 10 14 20 
Pt(2-picolylamine)Ox Mar9.1 0 0 8 25 
Pt(mmaei)I2 Mar1.5 -34 14 -1 -8 
Pt(mmaei)Cl2 Mar1.2 -29 15 10 -4 
Pt(mmaei)Br2 Mar1.3 -17 13 0 -8 
Pt(mmaei)Ox Mar1.1 -34 19 2 5 
Pt(mmabi)I2 Mar6.5 -37 14 -1 -19 
Pt(mmabi)Cl2 Mar6.2 -38 19 0 -17 
Pt(mmabi)Br2 Mar6.3 -31 15 -2 -19 
Pt(mmabi)Ox Mar6.1 -31 17 -2 -17 
Pt(maep)I2 Mar8.5 6 5 2 22 
Pt(maep)Cl2 Mar8.2 13 -3 6 28 
Pt(maep)Br2 Mar8.3 8 3 2 24 
Pt(maep)Ox Mar8.1 27 -43 -11 41 
 
Not much can be derived from the data, except that evidence is given of 
complexation. 
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5.3 DISCUSSION OF MASS SPECTRAL DATA OF AMINE COMPLEXES 
The factors discussed above were considered in this study of amineplatinum(II) 
complexes and the results will be described in paragraphs in which the common 
factor will be the non-leaving group. The majority of these are bidentate ligands 
which interact with the platinum in the form of chelate rings enhancing the stability 
of the complexes. The general synthetic methods were described in chapter 2 and 
will only be referred to in case of significant differences. 
5.3.1 2-Methylaminopyridine (Mar9) as non-leaving group 
2-Methylaminoimidazole derivatives have been extensively studied in this 
laboratory.60 The abovementioned ligand can be regarded as the 6-membered 
aromatic amine analogue of 2-methylaminoimidazole (thus a 5-membered 
aromatic amine). A comparison of the platinum complexes of these two ligands 
seemed to be of interest from a coordination point of view. 
(i)        Halo complexes 
The diiodo complex (Mar9.5) was synthesized firstly, as in the case of the 
(NS)-ligands. The mass spectra of this compound are given in figure 5.2. The 
mass spectra were obtained from an acetonitrile solution in view of the insolubility 
of this complex in aqueous solution.  
Although there are a number of peaks shown in the positive ion mode, these can 
be ascribed to the molecular species as well as solvated species. The latter 
includes acetonitrile-solvated (major peaks) and aqua species. In the negative ion 
mode, only neutral species are indicated. The spectra can therefore be interpreted 
as indicating a relatively pure compound in the solid state. 
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Figure 5:2 Full scan mass spectrum of sample Mar9.5 in MeCN/H2O solution for positive    
ion (top) and negative ion mode (bottom) and structures of species observed 
(below) 
The mass spectra of the dibromo complex (Mar9.3) are given in figure 5.3 The 
spread of the peaks in the positive ion mode is similar to that of the iodo analogue 
except that the solvated species (methyl cyanide, water) are evenly distributed. In 
the negative ion mode, only the molecular species are indicated, thus again 
suggesting that the complex is in a relatively pure state. 
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Figure 5:3  Full scan mass spectrum of sample Mar9.3 in MeCN/H2O solution for positive    
ion (top) and negative ion mode (bottom) and structures of species observed 
(below) 
The mass spectra of the dichloro complex (Mar9.2) are shown in figure 5.4. It 
appears as if the ionization of the chloro species occurs to a smaller extent than 
those of the other two halo complexes in this solvent system. The most dominant 
peaks are those of the molecular species in both the positive and negative ion 
mode. 
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Figure 5:4 Full scan mass spectrum of sample Mar9.2 in MeCN/H2O solution for positive     
ion (top) and negative ion mode (bottom) and structures of species observed 
(below) 
(ii)        Oxalato complex 
The mass spectra of the oxalato complex are shown in Figure 5.5. This figure 
clearly illustrates the presence of the molecular species, with insignificant amounts 
of ionization indicated by a number of small peaks. 
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Figure 5:5  Full scan mass spectrum of sample Mar9.1 in MeCN/H2O solution for positive     
ion (top) and negative ion mode (bottom) and structures of species observed 
(below) 
5.3.2 1-Methyl-2-(methylaminoethyl)imidazole (Mar1) as non-leaving group 
The molecular structures of 1-methyl-2-(methylaminoethyl)imidazole are given in 
figure 5.6a and b. The imidazole ligand having a methylamino group has been 
studied previously in this laboratory. The above ligand was chosen to investigate 
the effect of stereochemical crowding on its action as anticancer agent. 
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                                       (a)                                                                      (b) 
Figure 5:6 Structure of 1-methyl-2-(methylaminoethyl)imidazole (a) ball-and-stick model 
and (b) space-filling model 
(i)        Halo complexes 
The mass spectra of the diiodo complex (Mar1.5) are given in figure 5.7. Some 
ionization to the monocationic species is again indicated. 
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Figure 5:7 Full scan mass spectrum of sample Mar1.5 in MeCN/H2O solution for positive     
ion (top) and negative ion mode (bottom) and structures of species observed 
(below) 
The mass spectra of the dibromo complex (Mar1.3) are given in figure 5.8. A 
significant amount of ionization is indicated. The aqua solvate appears to be 
somewhat more prominent than the acetonitrile one in the positive ion mode. The 
negative ion mode again only reflects the presence of the molecular species. 
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Figure 5:8  Full scan mass spectrum of sample Mar1.3 in MeCN/H2O solution for positive     
ion (top) and negative ion mode (bottom) and structures of species observed 
(below) 
The mass spectra of the dichloro complex (Mar1.2) are given in figure 5.9. A 
relatively small amount of ionization is indicated in the positive ion mode. The 
solvated species are about equally represented by aqua and acetonitrile 
complexes. The spectral data suggest a pure compound. 
 
Figure 5:9  Full scan mass spectrum of sample Mar1.2 in MeCN/H2O solution for positive     
ion (top) and negative ion mode (bottom) and structures of species observed  
(ii)        Oxalato complex 
The mass spectra of the oxalato complex are shown in figure 5.10. These data 
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reflect the absence of significant ionization. 
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Figure 5:10  Full scan mass spectrum of sample Mar1.1 in MeCN/H2O solution for positive     
ion (top) and negative ion mode (bottom) and structures of species observed 
(below) 
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5.3.3 1-Methyl-2-(methylaminobenzyl)imidazole (Mar6) as non-leaving 
group 
The mass spectra of the diiodo complex (Mar6.5) are given in figure 5.11. 
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Figure 5:11  Full scan mass spectrum of sample Mar6.5 in MeCN/H2O solution for positive     
ion (top) and negative ion mode (bottom) and structures of species observed 
(below) 
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The mass spectra of the dibromo complex (Mar6.3) are given in figure 5.12. In 
this complex, significant ionization is indicated, both to the monocationic and even 
the dicationic species. 
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Figure 5:12  Full scan mass spectrum of sample Mar6.3 in MeCN/H2O solution for positive     
ion (top) and negative ion mode (bottom) and structures of species observed 
(below) 
The mass spectra of the dichloro complex (Mar6.2) are given in figure 5.13. The 
spectrum suggests some ionization in the positive ion mode, and only the 
molecular species in the negative ion mode. The ionization seems to be 
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significantly less than that of the chloro-analogue. 
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Figure 5:13  Full scan mass spectrum of sample Mar6.2 in MeCN/H2O solution for positive     
ion (top) and negative ion mode (bottom) and structures of species observed 
(below) 
 
5.3.4 2-(Methylaminoethyl)-pyridine (Mar8) as non-leaving group 
The mass spectra of the diiodo complex is shown in figure 5.14. Sizable ionization 
occurs towards the monocationic species. 
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 Figure 5:14  Full scan mass spectrum of sample Mar8.5 in MeCN/H2O solution for positive     
ion (top) and negative ion mode (bottom) and structures of species observed 
(below) 
The mass spectra of the dibromo complex are shown in figure 5.15. In this case, 
the ionization to the monocationic species appears to be greater than that of the 
corresponding iodo complex. 
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Figure 5:15  Full scan mass spectrum of sample Mar8.3 in MeCN/H2O solution for positive     
ion (top) and negative ion mode (bottom) and structures of species observed 
(below) 
The mass spectra of the dichloro complex are shown in figure 5.16. The 
ionization in the chloro analogue appears to be relatively small, especially when 
compared to the bromo and iodo analogues. 
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Figure 5:16  Full scan mass spectrum of sample Mar8.2 in MeCN/H2O solution for positive     
ion (top) and negative ion mode (bottom) and structures of species observed 
(below) 
5.3.5 Concluding remarks 
A comparison of the extent of ionization of the halo complexes in this solvent 
system (CH3CN / water) unfortunately does not give a clear reflection of the 
situation in pure water (or serum), since the extent of solvation of the halide ion 
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increases in the direction chloride < bromide < iodide in the presence of 
acetonitrile due to the increase in covalent character in the same direction. This 
solvent system, however, was used to obtain significant solubilities. It can 
therefore be assumed that the ionization in pure water will decrease in the 
direction chloro > bromo > iodo. The smaller extent of ionization of the oxalato 
species is very clear from the species observed in solution from their mass 
spectra. 
5.4 MOLECULAR MODELLING 
It was decided to perform molecular modelling studies on these complexes to 
obtain more information regarding the structures of these complexes, in an effort 
to better understand their anticancer activity. This was accomplished by the use of 
a molecular modelling software package (SPARTAN ’04).  Energy–minimized 
molecular models (calculated via a semi-empirical, PM3 approach) of all the 
compounds were done.  The ball and stick models of the structures of the 
(NN)-platinum(II) complexes are shown in the following figures.            
                           
                       (a)                                                                         (b)                 
                          
                            (c)                                                                            (d) 
Figure 5.17: Ball-and-stick models of (a) Mar9.5 (b) Mar1.5 (c) Mar6.5 and (d) Mar8.5 
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      (a)                                                                    (b) 
                                              
                                (c)                                                                     (d) 
Figure 5.18: Ball-and-stick models of (a) Mar9.3 (b) Mar1.3 (c) Mar6.3 and (d) Mar8.3 
 
                                    
           (a)                                                                      (b) 
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                                 (c)                                                                         (d) 
Figure 5.19: Ball-and-stick models of (a) Mar9.2 (b) Mar1.2 (c) Mar6.2 and (d) Mar8.2 
                          
       (a)                                                                        (b) 
                                            
                                  (c)                                                                         (d) 
Figure 5.20: Ball-and-stick models of (a) Mar9.1 (b) Mar1.1 (c) Mar6.1 and (d) Mar8.1 
The greater “crowding” of the aliphatic nitrogen atom by the ethyl- and benzyl-
substitions as compared to the unsubstituted ones ((b) versus (a)) can clearly be 
seen. The angle of the phenyl plane of the benzyl group with reference to the 
square coordination plane is also illustrated.         
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5.5 ANTICANCER TESTING 
The percentage inhibition of the (NN)-complexes on the growth of three different 
cancer cell lines was tested and is shown in the following tables.   
Table 5:2 Cell growth inhibition assay results of (NN)-halo complexes on a cervical 
cancer cell line (HeLa) 
 % Inhibition STD dev 
Conc 
(µM) % Inhibition 
STD 
dev 
Conc 
(µM) 
Cisplatin 21 54 11 62 1 114 
Mar1.2 0 3 7 49 1 72 
Mar1.3 5 9 3 2 8 35 
Mar6.2 6 5 3 28 8 32 
Mar6.3 17 19 0 0 4 3 
Mar8.2 6 2 8 6 2 79 
Mar8.3 36 14 1 40 7 13 
Mar9.2 30 1 6 83 2 64 
Mar9.3 0 9 2 43 2 23 
In one case, namely Mar8, the anticancer action of the bromo analogue is 
significantly higher than that of the chloro analogue (see Mar8.3 versus Mar8.2). 
Table 5:3 Cell growth inhibition assay results of (NN)-halo complexes on a colon 
cancer cell line (HT29) 
 % Inhibition 
STD 
dev 
Conc 
(µM) 
% Inhibition 
STD 
dev 
Conc 
(µM) 
Cisplatin 45 3 11 64 1 114 
Mar1.2 5 4 7 37 2 72 
Mar1.3 7 10 3 8 3 25 
Mar6.2 3 3 9 7 5 88 
Mar6.3 14 3 1 0 14 3 
Mar8.2 11 6 8 52 2 79 
Mar8.3 25 11 1 30 12 13 
Mar9.2 27 2 6 64 1 64 
Mar9.3 12 10 2 42 3 23 
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The anticancer action of Mar9.2 can be regarded as comparable to that of 
cisplatin, especially at the higher concentration.  
Table 5:4 Cell growth inhibition assay results of (NN)-halo complexes on a breast 
cancer cell line (MCF7) 
 
% 
Inhibition 
STD dev 
Conc 
(µM) 
% 
Inhibition 
STD dev 
Conc 
(µM) 
Cisplatin 39 1 11 65 1 114 
Mar1.2 10 7 7 44 1 72 
Mar1.3 0 9 3 0 6 25 
Mar6.2 0 16 9 0 4 88 
Mar6.3 0 5 1 0 10 3 
Mar8.2 5 4 8 14 2 79 
Mar8.3 30 9 1 22 9 13 
Mar9.2 31 5 6 78 2 64 
Mar9.3 0 11 2 51 3 23 
Mar9.2 once again exhibits recommendable anticancer properties (larger than 
cisplatin at the higher concentration). 
 
Table 5:5 Cell growth inhibition assay results of (NN)-oxalato complexes on a cervical 
cancer cell line (HeLa) 
 
% 
Inhibition 
STD dev 
Conc 
(µM) 
% 
Inhibition 
STD dev 
Conc 
(µM) 
Cisplatin 21 54 11 62 1 114 
Mar1.1 1 10 5 4 4 45 
Mar6.1 0 11 4 5 8 37 
Mar8.1 19 5 3 32 5 33 
Mar9.1 0 7 5 5 4 48 
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Table 5:6 Cell growth inhibition assay results of (NN)-oxalato complexes on a colon 
cancer cell line (HT29) 
 % Inhibition 
STD 
dev 
Conc 
(µM) 
% Inhibition 
STD 
dev 
Conc 
(µM) 
Cisplatin 45 3 11 64 1 114 
Mar1.1 3 9 5 2 6 45 
Mar6.1 0 24 4 3 5 37 
Mar8.1 11 7 3 12 5 33 
Mar9.1 7 3 5 20 10 48 
 
Table 5:7 Cell growth inhibition assay results of (NN)-oxalato complexes on a breast 
cancer cell line (MCF7) 
 % Inhibition 
STD 
dev 
Conc 
(µM) 
% Inhibition 
STD 
dev 
Conc 
(µM) 
Cisplatin 39 1 11 65 1 114 
Mar1.1 8 6 5 5 2 45 
Mar6.1 0 5 4 0 7 37 
Mar8.1 0 11 3 6 12 33 
Mar9.1 3 6 5 12 3 48 
The anticancer activities of the oxalato analogues are surprisingly poor. 
5.5.1 Concluding remarks 
In general, the results are disappointing. In all of these potentially bidentate 
ligands, except in the case of 2-picolylamine, one hydrogen of the aliphatic amino 
group has been substituted by an alkyl and in one case a benzyl group. All of 
these had poor anticancer behaviour, except one of them, namely the 2-(2-
methylaminoethyl)pyridine ligand (Mar8), which forms a 6-membered ring of which 
the bromo complex has relatively good anticancer action towards all three of the 
cancer cell lines in spite of its relatively low solubility (0.114 mM in a saturated 
solution). The chloro complex also exhibited moderate anticancer action, but the 
anticancer potential of bromo complex was significantly greater than that of the 
chloro analogue. 
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The only other reasonably good anticancer agent is in one case the chloro and in 
another case the bromo analogue of 2-picolylamine (Mar9.2 and Mar9.3, 
respectively). In a parallel study performed in this laboratory, the analogous 
methylaminoimidazole complex of platinum(II) also had fairly good anticancer 
behaviour.60 The significant anticancer potential of the 2-picolylamine complexes 
can possibly be related to the lesser screening of its amine group.  
The increased hydrophobicity in association with the crowding of the nitrogen 
atom observed in most of the halo complexes discussed in this chapter seems to 
be a problem with respect to their anticancer activity. 
The oxalato species are all very poor anticancer agents, in spite of their greater 
aqueous solubility. 
In the next chapter, some platinum(IV) analogues of these amine complexes will 
be discussed in the form of the mononitrochloroplatinum(IV) compounds. 
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CHAPTER 6:    
MONONITROPLATINUM(IV) COMPLEXES 
6 INTRODUCTION 
In chapter 1, it was explained that platinum(IV) compounds, because of their 
greater kinetic stability, can be employed as precursors for platinum(II) complexes. 
The example of JM216 was given as an illustration of such a prototype. A further 
even more recent development in this direction was the production of 
mononitrotrichloroplatinum(IV) compounds, which were prepared by the action of 
NO2 gas in the presence of chloride, producing compounds like Pt(NH3)2Cl3NO2 
(this compound was labelled CPA-7 and showed very promising anticancer test 
results). The problem, however, is that up to now, no satisfactory synthetic method 
able to produce gram quantities of a product in a high degree of purity is known. A 
few publications (and even patents) have occurred in this connection. All the 
articles in the literature regarding the synthesis of CPA-7 agreed that at present 
there is no satisfactory method for its preparation. RCT (USA), a pharmaceutical 
firm which sponsored the University of Florida to investigate this matter, 
approached our laboratory for assistance. An extensive study in this field, i.e. the 
synthesis and mechanism of the reactions involved in the formation of the 
mononitrotrichloroplatinum(IV) species, was initiated in this laboratory. It was 
realized that the main obstacle was the extent of the ionization of the chloro 
species of the platinum(II) starting material. This resulted in side reactions greatly 
lowering the yield of the required product. In this chapter, therefore, the bulk of the 
work will be done on platinum(II) species having lower degrees of ionization, more 
specifically, oxalato species. Oxalatoplatinum(II) species were not previously 
studied with this purpose in any of the above instances. This could probably be 
related to the well-known reducing capability of oxalate, especially when treated in 
the presence of a strong oxidizing agent like NO2. No nitrooxalato species of 
platinum(IV) could be detected in the literature.  
The simultaneous equilibria involved in the case of monodentate chloro complexes 
would certainly be limited if the dicarboxylic species is used (e.g. the difference 
120 
between carboplatin and cisplatin). Oxaliplatin has been studied extensively in this 
laboratory and furthermore, it is known to exhibit excellent anticancer activity in the 
case of colon cancer. Studies were therefore directed using oxaliplatin and the 
synthetic method for the preparation of NO2/Cl chloroplatinum(IV) species. In light of 
the known lower extent of ionization which should limit the number of side reactions, 
and in spite of the reducing potential of oxalate, this complex was chosen for this 
experiment hoping that the additional stability that the diamine imposes on the 
complex will stabilize the system enough to prevent the unwanted redox reaction 
between the oxalato group and the NO2. This procedure met with almost 
instantaneous success, since a method was soon developed to produce the final 
product in a relatively high yield as well as purity (higher than 95 % purity). 
6.1 THE DEVELOPMENT OF AN IMPROVED SYNTHETIC METHOD FOR 
MONONITROCHLORO COMPLEXES 
The published method consists of a reaction in aqueous medium in the presence 
of one equivalent of chloride, bubbling NO2 gas through from a cylinder until the 
first blue colouration is observed.45 The reaction mixture is then stirred whilst 
bubbling air through, normally overnight, until the colour changes to yellow. 
Alterations of this method were studied extensively in this laboratory. 
Upon applying the published method, it was shown in this laboratory that this 
method produces the required products in a mere 20-25 % yield, of which the 
major contaminant is the tetrachloro instead of the nitro/chloro species.58 Further 
studies on the chloro complexes indicated that the extent of ionization of the 
chloro species was the major obstacle which led to the production of numerous 
species (side reactions) including the formation of hydroxo species apart from 
unreacted starting material. After various parameters in this reaction have been 
studied, the method was altered in two ways, namely: 
(i) No excess chloride was added. 
(ii) The solvent system was changed from pure water to a mixture of water 
and acetone to limit ionization. 
In such a way, higher yields of up to 47 % as well as a higher degree of purity 
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could be obtained, although high degrees of purity were still elusive. 
6.2 SYNTHESIS OF A MONONITROCHLORO COMPLEX OF AN OXALATO 
SPECIES 
The published method consists of a reaction in aqueous medium After these 
difficulties it was realized that more success could be achieved by using a 
oxalatoplatinum(II) species of a known preferably very successful anticancer agent to 
expose this to a similar treatment, viz. NO2 gas in the presence of chloride. The 
obvious choice was oxaliplatin, as stated earlier. Some aspects of the method were 
changed simultaneously with the different leaving group. The reaction of concentrated 
nitric acid on pure copper metal was used as a source of NO2 gas instead of the very 
expensive, heavy gas cylinder of NO2 gas employed in the literature. A 30 : 70 water : 
acetone mixture was used to limit  ionization and at the same time leave enough 
water for oxaliplatin to dissolve. With this method, yields in excess of 80 % and 
purities in excess of 95 % could be obtained on a gram scale. The following figure 
shows a chromatogram of this product, indicating 98 % purity (see chapter 2 for 
detailed procedure). 
 
Figure 6:1 Chromatogram of Mar4.1.4 indicating 98 % purity 
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# Name  Time [Min] Height [mAU] Area [mAU.Min] Area [%] RT Offset [Min]  
1 UNKNOWN 2.45  1.7  0.2  0.275 0.00  
2 UNKNOWN 4.55  5.4  0.9  1.031 0.00  
3 UNKNOWN 5.28  2.0  0.3  0.331 0.00  
4 UNKNOWN 6.32  0.6  0.1  0.150 0.00  
5 Mar4.1.4  6.80  405.2  86.8  98.214 0.00  
        
Total     414.8  88.3  100.000   
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6.3 CHARACTERIZATION OF MAR4.1.4 
A number of physical analysis procedures were conducted in order to investigate 
the characteristics of Mar4.1.4. The stability of this complex was evaluated in both 
the solid state as well as in solution. 
6.3.1 Solid state stability 
6.3.1.1 Thermogravimetric Analysis 
 
Figure 6:2 Thermogram of Mar4.1.4 
Mar4.1.4 crystallizes with two molecules of solvated water. This is clearly shown in 
the thermogram in figure 6.2 (6.9 % loss at 80ºC, corresponding to the loss of two 
water molecules). It is, however, stable up to approximately 250ºC, whereafter a 
30.6 % loss indicates the loss of DACH and NO2, whilst an 18.9 % loss at 
approximately 310ºC indicates the loss of the oxalato-group. 
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6.3.1.2 X-ray structure determination 
The crystal structure of Mar4.1.4 was determined by crystallographic analysis as 
described in chapter 2. The crystal structure is shown in figure 6.3. 
 
Figure 6.3: Crystal structure of Mar4.1.4 
6.3.2 Solution stability 
6.3.2.1 Aqueous solution stability 
In a study to determine the aqueous decomposition of Mar4.1.4, the percentage of 
Mar4.1.4 in solution decreased from 93.8 % to 82.6 % after 18 hours at 80ºC. This 
signifies the remarkable stability in pure water. Its stability towards biomolecules 
will be discussed in the next paragraph. 
6.3.2.2 Biomolecule solution stability  
Upon addition of Cys to a solution of Mar4.1.4, reduction to oxaliplatin occurs.  
This is clearly demonstrated in Figure 6.3, where the positive ions attributed to 
Mar4.1.4 (m/z478 and 495) are completely replaced by those of oxaliplatin 
(m/z397).  This observation implies that the anticancer activity observed in the cell 
line tests may well be due to the in situ formation of oxaliplatin from Mar4.1.4, and 
this compound can thus be considered as an oxaliplatin pro-drug.  
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Figure 6:4 Positive ion mass spectra comparing Mar4.1.4 (water/37°C/18 h) in the 
absence (top) and presence (bottom) of Cys.  
Reduction of Mar4.1.4 without the formation of thiol derivatives was an 
advantageous result, especially as this reduction led to the formation of a known 
anticancer agent. In this modality the thiol reducers facilitate reduction of the pro-
drug with the subsequent formation of the active species. 
6.3.3 Anticancer Activity 
In light of the promising preliminary anticancer results of Mar4.1.4, IC50 values of 
Mar4.1.4 as well as cisplatin and oxaliplatin were obtained and are shown in table 
6.1. 
Table 6:1 IC50 values of cisplatin, oxaliplatin and Mar4.1.4 for three different cancer cell 
lines 
Compound (100 µM) HeLa HT29 MCF7 
Cisplatin 10.8 8.1 14.3 
Oxaliplatin 11.9 12.3 6.2 
Mar4.1.4 4.8 3.1 5.9 
The above table speaks for itself. Mar4.1.4 has significantly lower IC50 values than 
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605.9 607.9 
426.3 
428.2 
401.1 
431.3 609.9 449.1 
471.2 305.3 628.9 395.1 640.7 355.3 603.9 696.9 496.8 686.8 562.9 337.1 516.0 550.8 
NL: 2.62E6 
Blank pos inf#6-26   
RT: 0.06-0.30  AV:  
21 T: + p Full ms [  
150.00-750.00]  
NL: 2.40E6 
ph6 cys pos  
inf#22-61  RT:  
0.24-0.59  AV: 32  
T: + p Full ms [  
220.00-750.00]  
Drug blank 
Drug + Cys + pH6 
[Mar4.1.4+NH4] + 
[Mar4.1.4+H] + 
[Oxaliplatin+H] + 
[Oxaliplatin+H] + 
[Oxaliplatin+Bistris+H] + 
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cisplatin and oxaliplatin for all the cells tested. An international patent has been 
filed for the behaviour of the compound. 
6.4 STUDIES RELATING TO THE OXIDATION OF 
DIAMMINEOXALATOPLATINUM(II) 
The same procedures developed in the case for oxaliplatin were now applied on 
other platinum(II)oxalato complexes with anticancer potential. The first one in this 
group was cis-diammineoxalatoplatinum(II) (Cisox). The precursor cisox was 
synthesized by two different methods: firstly the silver method, and secondly the 
direct ligand exchange method in which a mixed non-aqueous/aqueous solvent 
system was used which was recently developed in this laboratory. Both these 
methods have been described in chapter 2. 
6.4.1 Solid state stability 
6.4.1.1 Thermogravimetric Analysis 
 
Figure 6:5 Thermogram of Mar2.1.4 
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The thermal stability of Mar2.1.4 is remarkable if it is borne in mind that both N(-III) 
(NH3) and N(+III) (NO2) are found in the same molecule. Solid ammonium nitrite 
does not exist (due to autoxidation-reduction). It is therefore not surprising that the 
more or less total destruction of the compound occurs at approximately 260 ºC, 
leaving approximately only platinum as product. 
6.4.2 Anticancer activity 
The anticancer behaviour of the starting material, i.e. Mar2.1, as well as that of the 
platinum(IV)NO2Cl complex, Mar2.1.4, are represented in table 6.2. 
Table 6:2 Cell growth inhibition assay results of Mar2.1 (Cisox) and Mar2.1.4 on three 
different cancer cell lines  
 
% 
Inhibition 
STD 
dev 
Conc 
(µM) 
% Inhibition 
STD 
dev 
Conc 
(µM) 
Cervical cancer (HeLa)  
Cisplatin 21 54 11 62 1 114 
Mar2.1 (Cisox) 8 0 5 8 2 50 
Mar2.1.4 54 1 8 84 1 77 
Colon cancer (HT29)  
Cisplatin 45 3 11 64 1 114 
Mar2.1 (Cisox) 25 5 5 56 1 50 
Mar2.1.4 0 6 8 35 5 77 
Breast cancer (MCF7)  
Cisplatin 39 1 11 65 1 114 
Mar2.1 (Cisox) 6 6 5 18 4 50 
Mar2.1.4 29 3 8 74 2 77 
It can be seen that Mar2.1.4 showed significantly greater anticancer potential than 
Mar2.1 for both cervical and breast cancer cell lines. 
127 
6.5 STUDIES RELATING TO THE OXIDATION OF 2-
PICOLYLAMINEOXALATOPLATINUM(II) 
In light of the anticancer potential of Mar9.2, the oxalato complex [2-
picolylamineoxalatoplatinum(II)] of this ligand was also chosen for oxidation to the 
NO2ClPt(IV)-complex. The anticancer results are given in the next paragraph. 
6.5.1 Anticancer activity 
The anticancer acitivities of Mar9.1 as well as Mar9.1.4 are shown in table 6.3. 
Table 6:3 Cell growth inhibition assay results of Mar9.1 and Mar9.1.4 on three different 
cancer cell lines  
 
% 
Inhibition 
STD 
dev 
Conc 
(µM) 
% Inhibition 
STD 
dev 
Conc 
(µM) 
Cervical cancer (HeLa)  
Cisplatin 21 54 11 62 1 114 
Mar9.1 0 7 5 5 4 48 
Mar9.1.4 15 2 3 42 3 31 
Colon cancer (HT29)  
Cisplatin 45 3 11 64 1 114 
Mar9.1 7 3 5 20 10 48 
Mar9.1.4 0 7 3 17 2 31 
Breast cancer (MCF7)  
Cisplatin 39 1 11 65 1 114 
Mar9.1 3 6 5 12 3 48 
Mar9.1.4 3 7 3 38 2 31 
Although the platinum(IV) analogue was somewhat more successful than the 
corresponding platinum(II) complex, the anticancer results were not really 
promising and further studies were therefore not undertaken. 
6.6 FURTHER STUDIES 
The oxalato complexes of a further number of ligands were studied, namely those 
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of 1-methyl-2-(methylaminoethyl)-imidazole, 1-methyl-2-(methylaminobenzyl)-
imidazole, ethylenediamine and 2-(2-methylaminoethyl)pyridine. None of these, 
however, proved to be very promising anticancer agents. 
6.7 CHEMISTRY INVOLVED DURING THE REACTION OF NO2 ON 
PLATINUM(II) COMPLEXES 
Previous studies of NO2/NO on platinum(II) compounds in the literature followed 
the same colour sequence, especially when the reaction is performed at low 
temperature, namely, an intensely blue solution is obtained initially. This gradually 
changes to a green solution and ends up as a yellow product, for example, the 
dark blue [Pt(NO2)4(NO)H2O]- could be obtained at low temperatures. The above 
anion is very unstable since the coordinated water molecule is readily replaced by 
coordinating anions like chloride or bromide. This compound is strongly reducing 
and a green nitrosylchloroplatinum(IV) compound could be isolated at -20ºC, 
namely K2[Pt(NO2)2(NO)Cl3]. The solid had a coordinated NO bonded to the 
platinum at an angle (such an NO is generally accepted to be in the NO- state.) 
Upon oxidation of the green complex, a more stable yellow product is obtained. 
This contained a coordinated nitro group trans to a chloride. CPA-7 is a typical 
example. 
In conclusion, it seems that the best description of these reactions is the oxidative 
addition of an NO radical and simultaneous withdrawal of an electron to produce a 
bonded group best described as in the NO- state, having a weakly bonded water 
trans to it, thus a relatively unstable intermediate species. Upon addition of 
chloride, the H2O is replaced by a Cl-. The reaction sequence, thus, in the case of 
oxaliplatin, appeared to be the following: 
 
Pt(dach)Ox                   Pt(dach)Ox(NO)H2O                      Pt(dach)OxCl(NO)                      Pt(dach)OxCl(NO2)
H2O
NO2 (NO)
Cl- O2
blue                                              green                                      light yellow  
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CHAPTER 7:    
CONCLUSIONS 
 
(NS)-complexes 
The dominance due to the trans effect of the thioethereal sulfur atom in the 
(NS)-haloplatinum(II) complexes is very clearly illustrated by the great difference in 
the ionization rate between the diamine and (NS)-halo complexes. 
 
A comparison of the (NS)-halo complexes is hampered by the relatively great 
differences in aqueous solubilities and the necessity to revert to mixed 
aqueous/non-aqueous solvent systems in which cases the solvation is different to 
that of serum (aqueous). Comparisons could therefore not readily be made with 
respect to the behaviour in pure water. 
 
The anticancer activities of the (NS)-bromo complexes are similar to those of their 
chloro analogues, and in one case significantly better (see anticancer action of 
Mar14.3 versus that of Mar14.2). 
 
The original study involved a ligand having a thioethereal sulfur atom since these 
do not react irreversibly with platinum and has been referred to as a platinum 
reservoir. However, this study has shown that the trans effect of that sulfur atom in 
the halo complexes is so large that ionization occurs instantaneously, rendering 
these complexes inefficient as anticancer agents. 
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However, even in the case of the oxalato analogues where the trans effect seems 
to be totally absent, the compounds are in general poor anticancer agents, except 
for a single example (J7.1). This emphasizes the multiplicity of parameters 
operating simultaneously to influence the anticancer action of these complexes. 
 
(NN)-complexes 
In a few examples, the bromo analogue had superior anticancer action compared 
to the chloro species of the same non-leaving group (e.g. Mar8.3 vs Mar8.2). 
 
The assumption that a non-leaving group having a planar tail end at a sharp angle 
to the coordination plane has recommendable anticancer action does not seem to 
be valid in general as shown in chapter 5. 
 
Mononitroplatinum(IV) Complexes 
Thermodynamically and kinetically stable species could be synthesized in spite of 
the fact that the reducing oxalate and oxidizing NO2 are simultaneously involved. 
 
In contrast to trichloromononitroplatinum(IV) compounds, the oxalato analogues 
could readily be prepared both in high yields (> 80% ) and purities (> 98 % ). 
 
One of these viz. mononitrooxalatochloro(dach)Pt(IV)  (Mar4.1.4) has 
exceptionally good anticancer properties since its IC50 values for the three cancer 
cells tested, namely cervical, breast and colon cells are lower for all three cancer 
cell lines tested than those of both cisplatin and oxaliplatin. 
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Upon reaction of Mar.4.1.4 with S-containing biomolecules it was shown that 
oxaliplatin was an important product through reduction. Mar4.1.4 can thus be 
regarded as a pro-drug for oxaliplatin. 
 
Mar4.1.4 is stable in aqueous solution in the absence of reducing agents. The 
solid loses two molecules of solvated water at 80ºC and only decomposes at 
temperatures higher than 200ºC. 
 
An international patent has been filed on Mar4.1.4. 
 
Another prototype namely diammineoxalatonitrochloroplatinum(IV)  (Mar2.1.4) 
also has better anticancer properties than cisplatin for two of the cancer cell lines 
tested. 
 
A reaction scheme could be proposed for the stepwise formation of the species 
during the reaction of NO2 with the Pt(II) analogues. The initial reaction appears to 
be oxidative addition of NO. 
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